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1. Abbreviations 
 
 
AA – arachidonic acid 
Ab – antibody 
AC – adenyl cyclase 
Ag – antigen 
AKAP – A-kinase anchoring protein 
APC (gene/protein) – adenomatous polyposis coli 
AOM – Azoxymethane 
ATP – adenosine 5`-triphosphate 
b-FGF – basic fibroblast growth factor 
cAMP – cyclic adenosine monophosphate 
CBP – CREB-binding protein 
CD – cluster of differentiation 
CEA – carcinoembryonic antigen 
CIMP – CpG island methylator phenotype 
CIN – chromosomal instability 
CK-1 – casein kinase 1 
COX – cyclooxygenase 
CRC – colorectal cancer 
CRLM – colorectal cancer liver metastasis 
Csk – C-terminal Src kinase 
CTLA-4 – cytotoxic T lymphocyte antigen-4 
DNA – deoxyribonucleic acid 
DC – dendritic cell 
Dsh – Dishevelled 
EGFR – epidermal growth factor receptor 
EP – E Prostanoid receptor 
FAP – familial adenomatous polyposis 
FOBT –  fecal occult blood test 
FOXP3 – forkhead box protein 3 
GPCR – G-protein-coupled receptor 
GSK-3 – glycogen synthase kinase 3 
HLA – human leukocyte antigen 
HNPCC – hereditary nonpolyposis colorectal cancer 
HSC – hematopoietic stem cell 
IBD – inflammatory bowel disease 
IFN – interferon  
IGF-1 – insulin-like growth factor 1  
 
 
 
 
IGFBP-3 – insulin-like growth factor binding protein 3 
IL – interleukin 
IPEX – immune dysregulation, polyendocrinopathy, 
enteropathy and X-linked syndrome 
Lck – lymphocyte-specific protein tyrosine kinase 
LEF – lymphocyte enhancer factor 
LPS – lipopolysaccharide 
MHC – major histocompatibility complex 
MSI – microsatellite instability 
NF-B – nuclear factor kappa-light-chain-enhancer of 
activated B cells 
NK – natural killer 
NSAID – nonsteroidal anti-inflammatory drug 
p53 – protein 53  
PBMC – peripheral blood mononuclear cells 
PG – prostaglandin 
PI3K – phosphoinositide 3-kinase 
PKA – protein kinase A 
PKB – protein kinase B / AKT 
PPAR – peroxisome proliferator activated receptor 
PSC – primary sclerosing cholangitis 
PTK – protein tyrosine kinase 
SEB – staphylococcal enterotoxin B 
TAA – tumor-associated antigen 
TAMs – tumor-associated macrophages 
TCF – T cell factor 
TCR – T cell receptor 
TGF – tumor growth factor 
Th – T helper 
TME – total mesorectal excision 
TNF – tumor necrosis factor  
TNM – tumor, node, metastasis 
Tp53 – (gene) tumor protein 53 
Treg(s) – regulatory T cell(s) 
VEGF – vascular endothelial growth factor 
WHO – World Health Organization 
Wnt – wingless integration 1 
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3. Introduction 
 
Current treatment of solid cancers includes a multimodal approach [67,129,159]. New 
radiological modalities improve disease staging giving the surgeon valuable preoperative data 
and help the early detection of recurrent disease. Adjuvant chemotherapy and radiotherapy 
contribute to a prolonged life and increased survival [67,130]. All of the above modalities are 
relevant in the treatment of cancer in the colon and rectum, colorectal cancer (CRC). The 
overall treatment of CRC has improved in recent years, and the surgical procedure now has 
low complication and local recurrence rates [119]. Standardization of the surgical procedure, 
centralizing the surgery to centers with sufficient patient volume and increased radical 
resections (e.g. total mesorectal excision in rectal cancer) are some surgical advances in recent 
years. Laparoscopy has benefits on recovery after surgery [194] leaving the patients available 
for post-operative adjuvant therapy faster and may indirectly affect the oncologic outcome. In 
conclusion, treatment of primary CRC is fairly effective with 5-year survival above 90% if 
the cancer is confined to the submucosal layer of the primary site (Stage I disease, see later 
regarding CRC staging). However, many patients present with distant metastases, a condition 
that dramatically reduces the chance of long-term survival, thus leaving a significant 
challenge for future CRC treatment.  
CRC treatment can be directed towards three different stages of the disease. The first 
is the tumor formation, the second the primary cancer and the third is the systemic disease. 
The greatest future benefits in CRC treatment may not be at the level of the primary tumor, 
but in understanding early steps in disease development with respect to prevention, early 
detection and treatment, as well as in improved treatment of distant disease when it presents. 
Colorectal cancer develops from the bottom of normal crypts in the colon or rectum. It 
is a process thought to progress in multiple steps, both morphologically (adenoma to 
carcinoma sequence) [158] and at the level of the genome, with genetic and epigenetic 
alterations different from the normal intestinal epithelial cell [57]. Mutation of the 
adenomatous polyposis coli (APC) gene is considered a gatekeeper of early colorectal tumor 
development [136], directly affecting cytoplasmic -catenin levels. -catenin is the main 
mediator in the Wnt signaling pathway [63]. Recently, a novel interaction between the Wnt 
pathway and the PGE2-cAMP-PKA pathway was described in stem cells [73,83,186]. The 
PGE2-cAMP-PKA pathway is previously well characterized and shown to be relevant in a 
broad variety of cellular mechanisms. We set out to identify the novel interaction between the 
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two pathways and its relevance in cells from human CRC and in an animal model of CRC 
(Paper I). Furthermore, we describe the clinical course in patients after liver resection for 
colorectal liver metastasis (CRLM) and discuss this in relevance to tumor biology supporting 
the arguments for aggressive surgical and adjuvant treatment (Paper II). Our findings in 
patients with CRLM suggest that patient selection is important and a challenging task. Based 
on previous findings, we hypothesized that tumor immunology may play a role in the course 
of CRC [206]. We therefore investigated the relevance of regulatory T cells (Treg)-mediated 
anti-tumor immunity acting through the COX-2-PGE2 immunomodulating pathway with 
respect to outcome in patients with CRLM (Paper III). 
 
3.1 Colorectal cancer (CRC) 
 
Colorectal cancer (CRC) is the fourth leading cause of cancer deaths worldwide in both men 
and women (WHO, 2008). CRC is the cancer of the colon and the rectum and approximately 
two thirds are located in the colon. The disease is often considered as one, irrespective of 
location, but should probably be regarded as two distinct entities as biology, risk factors, 
treatment and outcome may differ [112,169]. Most CRCs (95%) are epithelial cancers 
(adenocarcinoma) that originate from glandular tissue. Other, rarer cancers in the colon and 
rectum are squamous cell carcinoma and lymphoma. For the purpose of this thesis, 
adenocarcinoma of the colon or rectum will be referred to as CRC. 
In Norway, 2405 and 1219 patients were diagnosed with colon and rectum cancer in 
2009, respectively (Cancer Registry of Norway). Norway thus has one of the world’s highest 
incidences of CRC (42.2 and 34.8 per 100,000 per year for males and females, respectively). 
The incidence in the Norwegian population has been increasing more than in neighboring 
countries, with assumed comparable risk exposure and genetic background [185]. The reason 
for this remains obscure, but may be explained by alterations in the risk factor exposure 
panorama at different time periods in the different countries. However, this is not an 
established fact, and the possibility of previously undetected genetic or environmental risk 
factors cannot be ruled out. For the last 5-year period this has leveled off and there was no 
increase in the CRC rates from 2005-2009 compared to the preceding 5-year period (Cancer 
Registry of Norway, 2009).  
Several countries are initiating screening programs to detect and treat early disease 
stages with the aim of improving long-term survival [85]. In Norway, a CRC screening pilot 
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study that involves full colonoscopy has been funded and will be initiated in the near future 
(NORCCAP-2, Cancer Registry of Norway). Fecal Occult Blood Test (FOBT) and flexible 
sigmoidoscopy have been tested in randomized clinical trials and have shown to reduce 
mortality from CRC [28]. While the sensitivity and the specificity of the FOBT have 
improved recent years, it is still not optimal. Sigmoidoscopy, on the other hand, has better 
sensitivity and specificity, and also has the advantage that adenomas can be removed during 
the procedure, reducing the incidence of later invasive cancer [27,36]. However, 
sigmoidoscopy is a procedure that involves cost-benefit discussions and provides discomfort 
for the patient. In addition, proximal cancers will require colonoscopy to be detected. A need 
for novel screening methods is emerging, and studies with respect to improving the screening 
quality are ongoing. Promising studies open for the possibility of using cancer-specific DNA 
methylation patterns in epithelial colorectal cells in human stools as a non-invasive screening 
test for CRC and adenomas [96]. Even though screening may detect early cancers, thus 
leading to increased chance of survival, this does not alter the fundamental problem that CRC 
incidence is high, and increasing in many countries as diets become more Westernized [35]. 
Consequently, a better understanding of risk factors and early CRC development must be 
persued. 
The main reason for death in connection with the presentation of primary CRC is 
complications associated with the onset of bowel obstruction (ileus). Ileus is a symptom seen 
in circumferentially growing tumors, most often located in the descending or sigmoid colon, 
and patients may present with a dangerous ileus state as the debut symptom. Tumors located 
in the cecum and ascending colon tend to grow outwards (exophytic growth) and patients are 
more likely to present symptoms of anemia and abdominal discomfort before any acute life 
threatening condition. However, as endoscopy (sigmoid- and colonoscopy) is becoming more 
available and patients are referred at an earlier stage, most CRCs are discovered before they 
cause total bowel obstruction and are surgically resectable at presentation. Few patients die 
from complications related to the primary cancer. Furthermore, the frequency of local 
recurrence after resection for primary CRC is relatively low (10-20%) [126,149] compared to 
the frequency of recurrence in distant organs (~55%). Local recurrence is more common after 
resection for rectum cancer than colon cancer [180], but the frequency of both has declined 
after the implementation of adjuvant chemotherapy and improved surgical techniques, 
especially after the introduction of neoadjuvant radiotherapy and total mesorectal excision 
(TME) of rectum cancer [54].  
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In colon cancer, the surgical resection technique is under evaluation with respect to 
whether the resection should include central lymph node stations or not [99,103,114]. Colon 
is attached to the posterior abdominal wall via mesocolon that contains lymph node stations at 
different distances from the intestinal segments they drain. A mesocolic resection line close to 
the colon removes lymph nodes in close proximity to the bowel leaving the possibility of 
remaining disease in distant lymph nodes. Resections close to the central departure of 
intestinal vessels includes more draining lymph nodes, increasing the chance of total surgical 
removal of malignant cells. Central resection however, is technically challenging and may 
cause intraoperative or post-operative complications as it may threaten the circulation to the 
anastomosis introducing increased risk of anastomosis leakage, a dangerous complication 
associated with high mortality and increased risk for local recurrence [131].   
Cancer cells metastasize from the primary CRC to distant organs via blood or lymph 
circulation. The liver is the preferential target organ for malignant cells leaving the primary 
tumor and entering the circulation. Approximately 20% of the patients have detectable liver 
metastasis at the time of diagnosis (synchronous metastasis) and ~35% will develop 
metastasis in the following 5 years after surgery of the primary tumor (metachronous 
metastasis). Colorectal liver metastasis (CRLM) is the main cause of death in patients with 
CRC as ~55% of patients with CRC develop liver metastasis. Liver resection remains the only 
potential for cure but few are available for surgery because of extensive disease. The expected 
time of survival with synchronous CRLM  without any treatment is short [16].  
 
3.1.1 CRC staging 
Two different staging systems are used to provide prognostic information and determine 
treatment strategy in CRC. The Duke classification system from 1932 [52] has been replaced 
by the more detailed TNM staging system developed and maintained by the American Joint 
Committee on Cancer (AJCC). Duke staging is no longer recommended for use in clinical 
practice and is not further discussed here. TNM staging (tumor, node and metastasis) is used 
on many solid cancers, adapted for CRC and is now in the 7th edition as of 2010. As Table I 
shows, the tumor is first scored with respect to the TNM variables then assigned to stage I-IV 
in the CRC specific Table II. However, TNM does not adapt to recent advances in metastatic 
treatment. For example, the survival of a patient with resectable solitary liver metastasis is 
better than that of a patient with stage III disease [153]. Current observations regarding the 
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clinical course of the patients with CRLM (and our findings presented in paper II) support 
emerging arguments for a new staging system in CRC [152,153,191].   
 
TNM Disease extension
T1 Tumor invades submucosa
T2 Tumor invades muscularis propria
T3 a Tumor invades through the muscularis propria
b T1 or T2 tumor with satellite deposits in pericolorectal tissues
T4 a Tumor penetrates the visceral peritoneum
b Tumor directly invades or is adherent to other organs or structures
N0 No regional lymph node metastasis
N1 a Metastasis in 1 regional lymph node
b Metastasis in 2 to 3 regional lymph nodes
N2 a Metastasis in 4 to 6 regional lymph nodes
b Metastasis in 7 or more regional lymph nodes
M0 No distant metastasis
M1 a Metastasis confined to one organ or site (e.g., liver, lung, ovary, non-regional node)
b Metastases in more than one organ/site or the peritoneum.  
Table 1. The 7th edition of the AJCC-TNM classification system. T; tumor stage, N; lymph node involvement, M; distant 
metastasis. 
  
Stage T N M
I T1 N0 M0
T2 N0 M0
II a T3 N0 M0
b T4a N0 M0
c T4b N0 M0
III a T1-T2 N1 M0
T1 N2a M0
b T3-T4a N1 M0
T2-T3 N2a M0
T1-T2 N2b M0
c T4a N2a M0
T3-T4a N2b M0
T4b N1-N2 M0
IV Any T Any N M1  
Table 2. The 7th edition of the AJCC-TNM classification system. Staging of CRC from I to IV based in the TNM stage. 
 
3.1.2 Risk factors for the development of CRC  
Risk factors associated with CRC are either internal (genes/stimuli) or environmental. Some 
risk factors are known, but as indicated in the previous, unidentified risk factors cannot be 
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ruled out. Increasing age [9] and a family history of CRC [33] predispose to the development 
of CRC, and CRC is slightly more common in men. Furthermore, genetic conditions such as 
familial adenomatous polyposis (FAP) [78], Lynch syndrome (formerly HNPCC; hereditary 
nonpolyposis colorectal cancer) [65] and Gardner’s syndrome (considered a subtype of FAP 
[74]) are genetic risk factors. The FAP syndrome accounts for approximately 1% of all CRC 
cases and patients will most likely present with adenocarcinoma before the age of 40. 
Therefore, prophylactic colectomy is recommended at an early age for FAP patients [193]. 
Gardner’s syndrome is a rare phenotypic variant of FAP, both caused by mutation in the APC 
gene. In addition to colon polyposis, Gardner patients acquire extra-colonic tumors including 
osteomas, thyroid cancer, epidermoid cysts, fibromas, sebaceous cysts and desmoids tumors 
[74]. The disease is not curable and life expectancy with the condition is 35-45 years. Lynch 
syndrome is an autosomal dominant trait (as FAP) predisposing for CRC, the associated 
mutations impair genes related to DNA mismatch repair. Approximately 1-4% of the cases of 
colon cancer are related to Lynch syndrome [65]. Interestingly, FAP in contrast to Lynch 
syndrome seems to be more responsive to chemoprevention by COX inhibition [31], a 
mechanism that will be discussed in the following sections.   
Patients with inflammatory bowel disease (IBD, ulcerative colitis and Crohn’s disease) 
have increased risk of developing CRC and the risk is more likely a result of chronic 
inflammation rather than genetic predisposition [190].  The progression from adenoma to 
carcinoma that occurs during development of sporadic colorectal tumors (discussed in the 
next section) appears to be a sequence of inflammation – dysplasia – carcinoma in IBD-
associated CRC [190]. Primary sclerosing cholangitis (PSC) is another chronic inflammatory 
disease associated with CRC when concomitant with IBD [18]. Pro-inflammatory factors of 
the innate and adaptive immune system contribute to the development and growth of colon 
neoplasia.   
The geographical difference in CRC incidence is interesting (Central Africa: 2.3 per 
100,000 per year, Japan: 49.3 per 100,000 per year) and modifiable lifestyle factors are 
thought to contribute substantially to these variations [43] (Figure 1). Physical inactivity has 
been linked to the CRC diagnosis group as a whole, but not convincingly for rectal cancer 
alone [44,164,198]. Mutations in the genes K-ras and Tp53 are highly relevant for CRC 
development and the same mutations have been linked to reduced physical activity, smoking 
and diets high in red meat [26]. Regular exercise may increase the number and activity of 
macrophages, natural killer cells, and cytokines with the ability to kill cancer cells and 
thereby improve anti-tumor immune responses [203]. Furthermore, obesity may be a risk 
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factor for CRC development independently of inactivity. Visceral adiposity is associated with 
low-grade chronic inflammation leading to up-regulation of the nuclear transcription factor-
B (NF-B) with transcription of genes that promote tumorigenesis as a consequence [50].  
Prostaglandin E2 (PGE2) is reduced with high levels of physical activity, possibly 
through insulin-like growth factor-1 (IGF-1) [124] and our findings show that PGE2 affects 
both tumor immunity and tumorigenesis (Paper I and III). The motility of the intestine may 
affect CRC risk as shortened intestinal transit time reduces the exposure of the mucosa to 
faecal carcinogens. Exercise is thought to increase the expression of PGF2 and the vagal tone, 
both stimulating motility. Diets high in fiber, fresh fruits and fresh vegetables may also 
shorten the intestinal transit time and the formation of fiber may produce mucosa-protecting 
agents, thereby affecting CRC risk. However, studies regarding diet, transit time and CRC 
risk are contradictory and firm conclusions cannot be drawn [8,20,25,145].  
Insulin and insulin-like growth factor-1 (IGF-1) are up-regulated in the absence of 
physical activity and in obesity [44]. Increased levels of insulin and IFG-1 are correlated with 
risk of CRC [72]  possibly through mechanisms that activate the Wnt pathway and increase 
the expression of pro-angiogenic proteins such as HIF-1 and VEGF [50]. Furthermore, 
elevated levels of the reciprocally expressed insulin-like growth factor-binding protein-3 
(IGFBP-3) have been shown to be associated with reduced risk of CRC [91].  
 
 
 
Figure 1. Lifestyle factors associated with risk of developing CRC (red boxes) and selected possible molecular mechanisms 
(blue circles) that are suggested to connect risk factors and mechanisms towards CRC development (green boxes). Fat lines 
indicate mechanisms relevant for this thesis. 
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It is too early to establish a causal relationship between smoking and CRC, however 
most reports point in the direction that smoking is a risk factor [44,93]. Furthermore, smoking 
may be associated with different subtypes with different mutational background than non-
smokers (e.g. Tp53, APC and K-ras) [48]. Heavy alcohol intake (>45g/day) has been 
associated with increased risk of CRC, while lower levels were not [41]. The increased CRC 
risk has been suggested to be associated with lower intake of folate connected with heavy 
drinking [80].  
To conclude, there is evidence that inactivity, red meat, smoking, alcohol, and obesity 
are connected to increased risk of CRC, but the quality of the observations varies and in some 
cases, there are contradictory reports. With the geographical differences of CRC in mind, 
risk/protective factors are an important field and if properly understood, could save many 
lives. 
 
3.2 Tumor biology in colorectal cancer 
 
The adenoma – carcinoma sequence is a well known and accepted theory describing the 
development of colorectal cancer. It involves multiple steps of both genetic and morphologic 
transformation [57,109]. In the morphologic transformation, the first step is recognized as a 
dysplastic crypt or an aberrant crypt focus and this step may initiate the formation of an 
adenomatous lesion or an adenoma. Subsequently, some adenomas undergo malignant 
transformation to carcinomas (Figure 2).  
 
 
Figure 2. Adenoma – carcinoma sequence of development from normal mucosa to carcinoma. Arrows indicate associated 
mutations at given step.  
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Genetic alterations are also thought to progress in a multistep model at different stages 
in the adenoma – carcinoma sequence. One of the first (“gate-keeper”) steps is mutation of the 
adenomatous polyposis coli (APC) gene leading to inactivation of the APC protein [136], 
which normally serves as a growth control of the colon epithelium, followed by activation of 
the oncogene K-ras [136], and inactivation of the tumor suppressor gene Tp53 [11]. A 
mutation in the K-ras gene acts as a molecular “on”-switch, leading to recruitment and 
activation of proteins necessary for the propagation of cell growth. In a clinical setting, 
mutations in the K-ras gene are relevant by predicting the tumor’s response to epidermal 
growth factor receptor (EGFR) inhibiting drugs (chemotherapy), thus K-ras positive tumors 
will respond poorly to these agents [115]. Tp53 encodes the tumor suppressor protein p53, 
which is important in cell cycle regulation and therefore relevant in cancer. The APC, K-ras 
and Tp53 mutations are associated with chromosomal instability (CIN) [110], a molecular 
subtype of CRC [107]. However, accumulating evidence indicates that the adenoma – 
carcinoma sequence is a too simplified model of a process that in fact is far more complicated 
and heterogeneous. At least three distinct molecular pathways that promote tumor growth 
have been described to be activated in CRC, supporting arguments that CRC could constitute 
several different genetic diseases, all affecting the same organ [140,165]. The CIN pathway, 
as described, is the main pathway and is observed in up to 70% of CRCs. Microsatellite 
instability (MSI) occurs in up to 15% of CRCs and is caused by inactivation of DNA 
mismatch repair genes (MMR) [22]. CpG (-Cytosine-phosphate-Guanine-) island methylator 
phenotype (CIMP) refers to a widespread hypermethylation (epigenetic modification that 
represses transcription via the promoter region of tumor suppressor genes) of CpG island loci 
and is demonstrated in up to 20% of CRCs [104]. All of the above pathways can overlap and 
the significance of these overlapping features is not fully understood [140].  
 
3.2.1 The Wnt pathway, -catenin and adenomatous polyposis coli 
The APC gene is a tumor suppressor gene. In humans, APC mutations can be acquired 
(spontaneous CRC) or inherited, as in the autosomal dominant FAP syndrome, characterized 
by the formation of multiple colonic adenomatous polyps [78]. Inactivation of both APC 
alleles (APC-/-) is considered necessary for tumor formation and patients with FAP carry a 
heterozygotic mutation, thus leaving the chance of double mutations much higher than in 
individuals that carry the wild type sequence. The APC protein forms a destruction complex 
with Axin, glycogen synthase kinase 3 (GSK3) and casein kinase 1 (CK-1) [120]. The 
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destruction complex phosphorylates -catenin at Ser45, Thr42, Ser37 and Ser33, the first by 
CK-1, the three latter by GSK3 [186], and the indicated phosphorylation targets -catenin to 
degradation by the proteasome system [1] (Figure 3).  
In the absence of a normal APC protein, Axin, GSK3 and CK-1 cannot associate and 
form the destruction complex. The consequence is cytoplasmic accumulation and subsequent 
translocation of -catenin to the nucleus [179]. -catenin, originally discovered as a cadherin-
binding protein, is the main mediator in the Wnt (wingless and integration 1) pathway and has 
been shown to interact with and function as a coactivator of T-cell factor/lymphocyte 
enhancer factor (TCF/LEF) transcription factors [63]. Human transcription factor 4 (hTCF-4), 
a TCF family member that is expressed in human colonic epithelium and colon carcinoma 
cells, transactivates transcription only when associated with -catenin [29,100]. The result is 
expression and production of mitogenic and survival genes including c-Myc [81], cyclin D1 
[187] and cyclooxygenase-2 (COX-2) [53]. 
 
 
 
Figure 3. -catenin is the main mediator in Wnt signaling. The destruction complex composed of GSK3, Axin, CK1 and
APC phosphorylates and thereby targets -catenin to proteosomal degradation. In the absence of APC/destruction complex
-catenin accumulates in the cytosol and subsequently translocates to the nucleus. 
3.2.2 Cyclooxygenase-2 in colorectal cancer 
Cyclooxygenase (COX) exists in three isoforms. COX-1 is constitutively expressed in a wide 
range of cells and COX-2 is expressed in intestinal and other selected tissue in response to the 
pro-inflammatory cytokines lipopolylsaccharide (LPS), interleukin-1 (IL-1) and tumor 
necrosis factor- (TNF) [51,58]. COX-3 is a splice variant of COX-1, thus by some named 
COX-1b or COX-1variant (COX-1v) [39]. COX-2 expression is elevated in inflammation as 
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well as in several cancers and shown to promote tumor growth via one of its products, PGE2. 
COX-2 is expressed in 50% of colorectal adenomas and in 85% of human CRCs [53]. 
The enzymatic activity of COX cleaves arachidonic 
acid (AA) to form different prostaglandins (PG), depending on 
the enzymatic machinery present in the particular cell type 
(Figure 4). Prostaglandin E2 (PGE2) has been shown to be an 
important mediator of COX-2 associated effects, and PGE2 
levels are elevated in CRC biopsies compared to normal 
mucosa and even in patient blood samples [206]. PGE2 binds 
four cognate prostanoid receptors EP1-4, all part of the G 
protein-coupled receptor (GPCR) family. EPs activate G 
proteins and signaling downstream by increasing the 
intracellular levels of the second messenger cyclic adenosine 
3`,5`-monophosphate (cAMP, EP2 and EP4) or 
phosphoinositide (PI) signal transducers (EP3) inducing a 
decline in cAMP. EP1 induces calcium mobilization and constitutes a “contractile” receptor 
group. However, the effects of prostanoids on these G-protein coupled signaling pathways 
may change as a function of ligand concentration or structure. 
Figure 4. COX-2 cleaves AA to
form different prostaglandins (here
PGE2). COX-inhibitors (here
indomethacin) block the enzymatic
activity of COX-2. 
PGE2 stimulated EP receptor signaling events promote tumor growth by a broad range 
of mechanisms, and COX inhibition is therefore very interesting and relevant in CRC [197]. 
Peroxisome proliferator activated receptor  (PPAR) promotes tumor cell survival through 
inhibition of apoptosis and has been identified as a direct transcriptional target of the APC--
catenin-TCF pathway which confirms the relevance in CRC. PGE2 has been shown to 
transactivate PPAR and thereby inhibit apoptosis. Subsequently, pharmalogical inhibition of 
COX may promote apoptosis [171]. Moreover, PGE2 induces the expression of NF-B, a key 
anti-apoptotic mediator [151].  
The Ras-MAP kinase cascade is one of the major intracellular pathways responsible 
for cell proliferation and has been shown to be activated by PGE2 [196], thus mediating the 
stimulatory effects of COX-2 on cell proliferation and transformation [202].  
The expression of epidermal growth factor receptor (EGFR) on CRC cells directly 
correlates with the ability of the CRC cells to metastasize to the liver. Crosstalk between 
COX-2-PGE2-PKB and EGFR-PI3K-PKB pathways stimulates cell migration to a further 
extent than EGFR alone, providing evidence that COX inhibition may block the spread of 
metastatic disease. COX-2 and PGE2 over-expression has been shown to correlate with CRC 
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risk and metastasis of CRC, making this pathway relevant also in follow-up after treatment of 
the primary cancer [188].  
Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) 
are angiogenic factors induced by COX-2 overexpression in CRC and important for growth 
and survival of endothelial cells, as well as stimulation of vascular endothelial cell migration 
and capillary formation. Reports have indicated that the pro-angiogenic effects of COX-2 are 
mediated through PGE2 [82,177] and NSAIDs are shown to have anti-angiogenic effects in 
CRC through these mechanisms [125,167,174,189]. 
Local inflammation at the site of solid malignancy leads to accumulation of CD4+ T 
cells and CD8+ T cells as well as other immune cells; tumor-associated macrophages (TAMs), 
monocytes, mast cells, neutrophils and natural killer (NK) cells. Tumor and surrounding 
stromal cells express chemoattractants and release them locally. The chemoattractants 
stimulate migration and the infiltration of immune cells and are closely linked to further 
tumor progression. Furthermore, COX-2 overexpression by CRC cells may also contribute to 
maintaining a chronic inflammatory state in the tumor and in the tumor vicinity as well as 
promoting a shift in the tumor microenvironment to an immunosuppressive dominance, 
preventing an effective anti-tumor immune response.   
 
3.2.3 Animal models studying COX-2-mediated effects in colorectal cancer 
The study of cancer in humans is a complicated endeavor, in which ethical aspects and 
individual considerations often take priority over the research objective. Furthermore, humans 
are exposed to a variety of known and unknown environmental factors and the genetic 
heterogeneity can be a challenge when studying biologic mechanisms. Animal models may 
therefore offer opportunities to study biology in vivo where humans are not available or 
suitable. However, ethical guidelines must be strictly followed also when conducting animal 
experiments and the animals should not be exposed to distress beyond the purpose of the 
study. Alternatives to animal experiments should be considered in each case, if the biological 
effects could be studied in assays not involving animals.  
By using a human colon cancer cell line we showed that inhibition of the COX-2–PGE 
–cAMP–PKA pathway, at the level of PKA, affected the Wnt pathway. We therefore wanted 
to investigate this in an intestinal tumor model in vivo. Three different animal models have 
been used to test the ability of COX inhibiting agents on CRC in the past. Azoxymethane 
(AOM) treated rats develop aberrant crypt foci, which are pre-neoplastic lesions that later 
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progress to carcinomas in the colon [116]. The xenograft mice model, in which cultured 
colorectal cancer cells are xenografted on the flanks of nude (athymic) mice, has also been 
used [199]. Tumor volume is measured over time in response to various treatments. The third 
and most known model is developed from C57BL/6J mice treated with ethylnitrosourea 
followed by selection for transmission of germ-line mutations. The relevance of this model to 
human disease was apparent when the phenotype was mapped to a mutation in the APC gene 
and thereby the name ApcMin/+ mice [182]. The ApcMin/+ mouse is a well-established model of 
FAP with a germline mutation in one APC allele, thus increasing the probability of a double 
allele mutation and tumor formation.  ApcMin/+ mice develop multiple adenomas in the 
intestinal tract, mainly in the small intestine, at an early age which can be blocked effectively 
by COX inhibition through non-steroid anti-inflammatory drugs (NSAIDs, [15,24,87,88] and 
our results). In paper I we used the ApcMin/+ model to study effects of COX and protein kinase-
A (PKA) inhibition on tumor formation and interactions with the Wnt pathway.  
 
3.3 Metastatic colorectal cancer 
 
Metastasis from colorectal cancer (CRC) to the liver (colorectal cancer liver metastasis; 
CRLM) is common [92]. About 20% of the patients present with synchronous metastases at 
the time of diagnosis and 35% of the patients will later develop metachronous liver metastases 
[105]. Patients with untreated liver metastases are typically thought to have an expected 
median survival of less than 6 months [16,111]. Hepatic resection remains the only potentially 
curable treatment and is now offered to 20-25% (Figure 5) of the patients whereas only 10% 
were selected for this treatment ten years ago [146]. The main exclusion criteria for liver 
resection of CRLMs are non-resectable metastasis (tumor growth into both portal branches 
and/or into both left and right liver vein), inadequately functioning residual liver parenchyma 
or non-resectable extrahepatic disease. However, these exclusion criteria have all been 
challenged in recent years. Close follow-up after primary CRC (early detection of metastasis), 
implementation of new surgical techniques including two-stage hepatectomy with portal vein 
embolisation [4,89] and transplantation methods, and the introduction of new chemotherapy 
and biological agents capable of converting inoperable cases to a resectable status by tumor 
downsizing [3,106,111] have increased the number of patients eligible for resection of liver 
metastases. Patients with resectable liver metastases have an estimated 5-year survival of 35-
50% for selected cases [49]. However, in the recurring population a significant proportion 
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develops rapidly progressing non-re-
resectable disease even though receiving 
chemotherapy, and for those the benefit 
from surgery is questionable [111].  
On this background, patient 
selection is important and predictive 
factors for the oncologic outcome after 
resection of CRLM should be pursued. 
Different predicting tools for survival in 
patients with resectable CRLM have been 
proposed. Eight different scoring systems 
with data from more than 300 patients 
with resectable CRLMs in each are 
presented in Table 3 
[60,86,94,123,128,137,157,208]. All 
registered data retrospectively and used 
Cox proportional hazards regression to 
identify risk factors associated with survival, presented in Table 3. Five of the studies 
(Nordlinger et al., Fong et al., Iwatsuki et al., Rees et al. (referred to as the Basingstoke 
Predictive Index, BPI) and Kattan et al.) present sets of clinical parameters and merge them to 
produce a predictive score for the disease-specific survival after resections for CRLM 
[60,86,94,137,157]. Zakaria et al. found only preoperative blood transfusion and positive 
lymph nodes to be of significant importance and question the value of risk scoring systems 
[208], while Malik et al. found an inflammatory response parameter based on plasma 
concentrations of C-reactive protein (CRP) or neutrophil/lymphocyte ratio of more than 5:1 
[123] to be significant markers. Furthermore, Minagawa et al. propose a simplified algorithm 
to determine the disease stage (defined stage 1 to 4) in CRLMs based on 369 patients and 
interestingly they use 229 unrelated patients to validate their simplified scoring system [128].   
Figure 5. Simplified schematic presentation of the patient
population with CRC and CRLMs. Treatment possibilities at
different levels and final outcome. ChTh; chemotherapy, TX;
transplantation, RF; radiofrequency. 
In paper II we examined clinical outcome after surgery for CRLM and how this may 
support aggressive treatment strategies. Our findings challenge the use of traditional risk 
factors to decide on treatment strategy. Thus, we suggest that the search for novel markers 
must continue. Furthermore, clinical parameters may only represent a mirror of the tumor 
microenvironment where the tumor biology and the extracellular context are primary and 
secondary determinants for progression, respectively. Clinical parameters may therefore not 
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be the best predictors. In paper III, we examined whether tumor immunology could affect the 
clinical outcome. Our results indicate that future prognostication may involve novel biological 
and immunological markers.  
 
Predictive factors after 
resection for CRLM
Nordlinger 
(n=1513)
Fong 
(n=1001)
Iwatsuki 
(n=305*/243)
Minagawa 
(n=369/229**)
Zakaria 
(n=663)
Malik 
(n=687)
Rees 
(n=929)
Kattan 
(n=1477)
General parameters
Gender X
Age X X
DF interval from PT to LM X X X X
The primary tumor
Site colon/rectum X
LN status X X X
Differentiation grade X
Stage X
The liver metastasis
Number of metastases X X X X X X
Size largest tumor X X X X X
Bilateral disease X X
Number of lobes X
Hepatic resection margin X X X * X
Regional lymph nodes X X * X X
Extrahepatic disease X X
Blood transfusion X
Biochemical
CEA at hepatectomy X X X X X
Inf lammatory response X
X
 
Table 3. Clinical and biochemical factors reported in indicated studies to be predictive factors with respect to disease-specific 
survival after resection for CRLMs. *Denotes factors reported in 305 patients including patients with evidence of 
extrahepatic disease. **Unrelated validation cohort. DF; disease-free, PT; primary tumor, LM; liver metastasis. 
 
3.4 Cancer immunity 
 
From an evolutionary point of view the immune system is designed to protect the organism 
from foreign microbes such as bacteria, virus and fungi. As modern medicine has evolved, 
treatment of infections has improved and cancer is now a leading cause of death, accounting 
for 13.3% of all deaths worldwide (WHO, 2008). Increasing age is associated with many 
cancer forms. From a theoretical perspective, cancer incidence increases as more people 
survive other potential causes of death. Efforts should be made to improve knowledge of CRC 
biology and risk factors with the aim to prevent and treat the disease. In recent years, the 
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recognition that solid tumors contain infiltrates of immune cells and that cancer patients have 
higher prevalence of circulating regulatory T cells (Tregs) that potentially prevent a beneficial 
anti-tumor immune response, has lead to the hypothesis that the immune system may play a 
central role in the formation and progression of tumor development. Understanding 
mechanisms of anti-tumor immunity and tumor immune evasion could in the near future lead 
to development of strategies for prevention, discovery and treatment of cancer. 
 
3.4.1 The adaptive immune response and T cell-mediated immunity 
The task of the immune system is simple; to recognize and destroy intruding pathogens, 
however, the mechanisms by which the immune system performs its task are highly complex. 
Most microorganisms that meet the host are rejected by internal and external surface barriers. 
About half of the microorganisms that break the barriers are eliminated by the innate immune 
system characterized by a direct and universal response. The main players of the innate 
immune system are phagocytic cells (neutrophile granulocytes, monocytes/macrophages and 
dendritic cells), cells that release inflammatory mediators (basophile and eosinophile 
granulocytes and mast cells), antimicrobial peptides and the complement system amplifying 
the innate immune response. Another important task of the innate immune system is to 
activate the adaptive immune system by presenting peptides from foreign antigens to the 
players of the adaptive immune system, B cells and T cells.  
The term immunologic memory is based on the ability of the immune system to 
remember a certain pathogen and thereby increase the response upon reinfection, which upon 
subsequent encounters leads to more efficient elimination of the pathogen. B cells represent 
the cellular basis of immunological memory and isotype-switched memory B cells, 
developing from naïve B cells, may differentiate to immunoglobulin producing plasma cells 
that migrate to the bone marrow and produce high affinity antibodies for several years. The T 
cell memory is based on the fact that there are more antigen specific cells than before the 
primary response, and that surface molecules with homing properties are present, thus the 
response is faster. 
Adaptive immunity is initiated by the presentation of antigen by the innate immune 
system to B and T cells, the players of the adaptive immune system. Macrophages and 
dendritic cells, commonly referred to as antigen presenting cells, are equipped with receptors 
that recognize molecular patterns that are characteristic for different microorganisms. Binding 
results in uptake and processing of the microorganism by the antigen presenting cells before 
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presenting it as foreign peptide (antigen) on MHC-class II molecules to the T cell receptor 
(TCR) in germinal centers of lymph nodes. A large number of naïve T cells circulate through 
the lymph nodes, and those with a TCR specific for a given antigen induce proliferation and 
clonal expansion of antigen-specific effector T cells (Figure 6). Depending on the cytokine 
milieu in the lymph node and the specific antigen presented, the T cells develop to either 
cytotoxic T cells (CD8+ T cells) or T helper cells (CD4+ T cells), the latter further developing 
into three different T helper subtypes; Th1, Th2 and Th17. Th1 with respect to cell-mediated 
immunity helping macrophages, the Th2 subtype affecting hormonal immunity helping B cells 
and Th17 cells involved in recruitment, activation and migration of neutrophils.  
 
 
Figure 6. Early innate immunity (white boxes) versus late adaptive immunity (green box). Antigens are transported
from site of infection by antigen presenting cells to lymphoid organs and presented to naïve B and T cells initiating
clonal expansion of antigen specific cells.  
 
Major Histocompatibility Complex (MHC) is found in all vertebrates, originally 
identified as an antigen system of the leukocytes, therefore called Human Leukocyte Antigen 
(HLA) in humans. The purpose of the MHC antigens is to serve as identity markers on the 
surface of different cells and present foreign antigen peptides (MHC-antigen complex) to the 
TCR on the surface of T cells and thereby cooperate with the T cell to exercise their adaptive 
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immune functions. MHC-class I molecules are expressed on the surface of all nucleated cells 
and present antigens to CD8+ cytotoxic T cells while MHC-class II molecules are expressed 
on the surface of antigen presenting cells and present antigens to CD4+ T helper cells. The 
CD4 molecule stabilizes the binding between the TCR and the MHC-class II and the CD8 
molecule is a co-receptor for MHC-class I. 
The T cell receptor undergoes random gene rearrangement in individual developing T 
cells, thus providing the huge diversity in the T cell repertoire. Each individual possesses 
millions of different TCRs with individual antigen specificity. The TCR consists of four units, 
the TCR and TCR unit forming a ligand-binding part and the two CD3 units forming a 
signal-transducing part. The binding of the MHC/peptide complex to the TCR sends the first 
activation signal to the T cell by triggering phosphorylation cascades downstream and finally 
resulting in transcription of genes involved in T cell activation and proliferation (TNF, IFN, 
IL-2 and CD69 among others) [121,156].  However, for full activation a second (co-
stimulatory) signal is required. The antigen presenting cells are equipped with CD80 and 
CD86 molecules interacting with the CD28 or the CTLA-4 co-receptor on the T cell, 
providing either activation and cytokine production or inhibition of T cell activation, 
respectively. Thereby, the T cell can fine-tune its immunologic machinery by receiving 
different co-stimulatory signals. T cells encountering antigen without co-stimulatory signaling 
undergo apoptosis or become anergic.  
 
3.4.2 T cell activation and regulatory effect of the cAMP - Protein kinase A pathway 
Downstream signaling from the TCR and co-receptors defines the fate of the T cell and is a 
highly complex pathway involving multiple phosphorylation steps and different mediators. A 
sufficient T cell defense is dependent on initial activation to clear the pathogen followed by 
inactivation, to switch the immunologic machinery off when the pathogen is cleared.  
Cyclic AMP is the first intracellular second messenger described [184] and important 
in many biological processes. It plays a crucial role in the intracellular signaling of many 
neurotransmitters, hormones, and other humoral factors, and regulates a wide range of cellular 
events such as cell division, gene expression, metabolism and regulation of immune responses 
[133]. In T cells cAMP is important to regulate the cell’s response to defined stimuli. Cyclic 
AMP is synthesized from adenosine 5`-triphosphate (ATP) by adenylyl cyclase which is 
located in the inner side of the plasma membrane. The synthesizing activity of adenylyl 
cyclase is activated upon binding of extracellular ligand to the G-protein coupled receptors 
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(GPCR) and subsequently dissociation of G and G subunits. The G subunit activates 
adenylyl cyclase [79].  
Protein kinase A (PKA) is a tetramer consisting of four subunits, two catalytic and two 
ts of PKA and an A-kinase anchoring 
protein (AKAP) positions the kinase in 
the vicinity of localized cAMP pools 
[134]. Each regulatory unit is also 
equipped with two binding sites for 
cAMP and cAMP binding dissociates 
two catalytic subunits from the PKA 
complex (Figure 7). The free catalytic 
subunits phosphorylate local target 
proteins, regulating their activity [173]. 
In T cells, one major target is C-terminal 
Src kinase (Csk) and activation and 
recruitment of the kinase is dependent on 
phosphorylation at Ser364 by PKA 
[192,205]. Activated Csk then 
phosphorylates and turns off Lck, a 
protein tyrosine kinase (PTK) closely 
linked to T cell activation allowing 
signaling through the TCR.  
 
regulatory. Interaction between the regulatory uni
 properties were discovered in 1970 [71]. Later, they were named 
Figure 7. PGE2 – cAMP - PKA pathway negatively regulates
signaling through the T cell receptor via activation of Csk and
inactivation of Lck (reviewed by Mosenden and Taskén 2011). 
3.4.3 Regulatory T cells 
T cells with suppressing
regulatory T cells (Tregs) after the finding that a suppressive subset of CD4+ T cells expressed 
CD25, the IL-2 receptor  chain [162]. However, identifying the regulatory T cell subset by 
CD4+CD25+ is not optimal as activated T cells also express CD25. The immune dysregulation 
polyendocrinopathy enteropathy X-linked (IPEX) syndrome is a rare disease in humans 
(spontaneous murine mutant; scurfy mice) and leads to extensive autoimmunity. 
Investigations to identify underlying causes of IPEX led to the discovery of the transcription 
factor forkhead box P3 gene (FOXP3) [17]. The suppressive function of Tregs is dependent 
on expression of FOXP3 and stable expression of the FOXP3 protein is restricted to Tregs. 
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FOXP3 developed as a marker for the suppressive T cell subset and remains the best marker 
for Tregs today [204]. However, several issues complicate the use of FOXP3 as a unique 
marker for Tregs. First of all, FOXP3 is expressed intracellularly and for the purpose of 
isolating a Treg population, surface markers like CD4, CD25, and CD127 would have to be 
used in order to yield live cells. Furthermore, T cells with a somewhat suppressive phenotype 
not expressing FOXP3 have been identified [142]. Finally, not all FOXP3+ T cells are 
functionally suppressive [209]. Several new candidate markers have been suggested and 
validated, including CD147 as a marker for activated Tregs [176], but so far none are unique 
and this remains a challenge for future Treg studies.   
 The transmembrane tyrosine phosphatase receptor CD45 antagonizes Csk by 
specific activation or polyclonal TCR stimulation to exert their 
suppres
pertoire of different suppressive mechanisms. They can 
target effector T cells (CD8+ cytokine producing T cells) directly.  Moreover, they can target 
dephosphorylating Lck, thereby allowing activation of Lck followed by signaling through 
TCR [141]. CD45 exists in many isoforms. Positively selected naïve T cells express CD45RO 
in the thymus, convert to CD45RA expression at the time of peripheral migration, and switch 
back to CD45RO after antigen recognition (effector/memory cells). A small percentage of 
antigen-experienced T cells revert from CD45RO+ to CD45RA+ as they undergo 
differentiation into terminal effector cells [14]. Recently, CD45RA proved useful as a marker 
and differentiator for different Treg subsets. Human FOXP3+ T cells were shown to comprise 
three distinct pheno- and functional types based on CD25 and CD45RA expression. Two of 
the subtypes, CD25++CD45RA+ and CD25+++CD45RA- were functionally suppressive resting 
and activated Tregs, respectively. The third Treg subtype based on the activation marker 
CD45, the CD25++CD45RA+ cells, were shown to be cytokine producing cells with lack of 
suppressive activity [132]. The latter finding adds to the discussion of using FOXP3 as a 
marker for suppressive cells. 
Tregs require antigen-
sive function but can suppress effector cells (CD4/8+ T cells and NK cells) in an 
antigen-nonspecific manner [21]. Thymus-derived naturally occurring Tregs (nTregs) are 
thought to suppress effector T cells in a cell-cell contact-dependent manner although receptors 
for contact are yet unknown [172]. However, Tregs with a naïve TCR repertoire can also 
leave the thymus and become induced in lymph nodes, spleen, gut-associated lymphoid tissue 
or inflamed tissue, and are thereafter called adaptive Tregs (aTregs). In addition to contact-
dependent suppression mechanisms (as for nTregs), the suppressive properties of aTregs can 
also be mediated by soluble factors. 
Adaptive Tregs possess a re
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accesso
er 
effecto
or infiltrating lymphocytes (TILs) are associated with improved prognosis in many 
of immune cells in CRC may have higher 
ents, Tregs expand, migrate to the tumor site and suppress anti-tumor 
immun
ry cells (dendritic cells), possibly though CTLA-4 related mechanisms, and thereby 
indirectly influence effector T cell activation status. Contact-dependent inhibition may be 
mediated through granzyme expression and surface-bound inhibitory molecules causing 
cytolysis and inhibition of the effector T cell, respectively. Contact-independent inhibition is 
mediated through expression of soluble suppressor molecules and cytokines such as IL-10 and 
TGF- as well as adenosine or/and through IL-2 consumption, thus depriving surrounding 
cells of important survival cues and imposing cell-cycle arrest in the effector T cell [161].  
In addition, we previously showed that aTregs express PGE2 [122], thus providing 
another contact independent regulatory mechanism in which Tregs suppress bystand
r cells (Figure 7). PGE2 causes immunosuppression by suppression of T, B and NK cell 
immune responses through stimulation of EP-receptor signaling [134]. 
 
3.4.4 Regulatory T cells in colorectal cancer 
Tum
cancers and the type, density and location 
predictive power than the prognosis estimated by the conventional AJCC-TNM histological 
classification [68,143]. In addition, intrinsic immunosuppressive mechanisms in the adaptive 
immune system such as down-regulation of co-stimulatory receptors and up-regulation of 
inhibitory co-receptors, secretion of immunosuppressive cytokines and recruitment and 
induction of Tregs, contribute to the immunosuppressive microenvironment of solid 
malignant tumors [97]. 
Tregs are a T cell subset with dominant immunosuppressive properties and in cancer-
bearing animals and pati
e responses mediated by NK cells, CD4+ and CD8+ T cells through molecular 
mechanisms described in the previous [161]. While high numbers of other TILs such as 
CD3+, CD8+ T cells have shown to be associated with improved prognosis in CRC as well as 
other cancers, the infiltration and a high number of FOXP3+ Tregs are thought to play a 
significant role by suppressing the anti-tumor immunity, suggesting that this negatively 
affects the prognosis for the patient [42]. Suppression of adaptive anti-tumor immune 
responses in the tumor margin shields the tumor from the immune system and contributes to 
tumor immune tolerance [207]. Treg-mediated suppression of anti-tumor immune responses 
has been reported in a broad range of human carcinomas, including breast [13], ovarian [201], 
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lung [148], hepatocellular [69], renal cell [118], pancreatic [84], gastric [147] and cervical 
carcinomas [90].  
Patients with CRC are reported to have increased frequencies of CD25+FOXP3+ Tregs 
in peri
  
pheral blood and in tumor tissue (tumor infiltrating Tregs) [42,117,200]. Tregs in 
peripheral blood suppress anti-tumor immune responses, as observed by the ability to inhibit 
proliferation and cytokine release by effector T cells [23,42,117,200,206]. Furthermore, 
depletion of Tregs from peripheral blood mononuclear cells (PBMC) unmasks immune 
responses to tumor-associated antigens, e.g. 5T4 and CEA peptides, not seen in healthy 
controls [42,206]. The findings indicate that Treg-mediated inhibition of anti-tumor immune 
responses may also be specific to the tumor antigen (or tumor-associated antigen). This opens 
for the possibility to design specific cancer vaccines and testifies to the importance of 
controlling Tregs to the benefit of the anti-tumor immunity. Inhibition of Treg activity may 
represent a future therapeutic avenue to improve anti-tumor immunity. To examine the role of 
Treg activity versus clinical outcome in CRC, we followed patients undergoing liver resection 
for CRLM and their levels of Treg suppression of anti-tumor immunity (Paper III).   
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4. Aims of the study 
 
The aims of this study were to characterize the role of the PGE2-cAMP-PKA pathway 
dependent regulatory mechanisms in primary and systemic CRC with respect to biological 
and immunological mechanisms. When trying to improve the treatment of CRC, three stages 
of the disease can be targeted: i) the tumor formation, ii) the primary cancer and iii) the 
systemic disease with distant metastases. While the treatment of primary CRC (stage ii) is 
associated with low mortality and low frequency of local recurrence, primary prevention 
targeting tumor formation (stage i) may have better potential for patient benefit. Furthermore, 
many patients present with distant metastases (stage iii) after treatment for CRC, and this 
must be considered the main obstacle for long-term cancer-free survival in these patients. The 
work in this thesis was focused on stage i and iii.  
Previous work in our group made it possible to synthesize gram quantities of the 
cAMP analogue Rp-8-Br-cAMPS which offered the possibility to block the PGE2-EP2-
cAMP-PKA pathway in animal experiments. Based on recent reports of early steps in 
colorectal cancer tumor biology we found it interesting to study effects of perturbation of this 
pathway in a CRC animal model. Current treatment controls the primary tumor, but a large 
proportion of patients present with distant metastasis. We next therefore decided to study the 
course and outcome for patients selected for resection of CRLMs, with special focus on 
recently implemented treatment strategies. In previous work we had learned that regulatory T 
cells suppress anti-tumor immunity in primary CRC patients through a PGE2-PKA 
immunosuppressive mechanism [206]. Studying patients undergoing liver resection for 
CRLM we set out to discover whether tumor immunology could affect the course of the 
disease or not, and if this could provide valuable prognostic information in these patients.  
Specific aims of this study included: 
 
1. Does perturbation of the EP2/4 but not the EP3 signaling pathway by inhibition at the 
level of PKA affect -catenin levels and tumor formation in ApcMin/+ mice? 
2. Do new treatment strategies applied to CRLM patients improve survival?  
3. Does the level of Treg-mediated suppression of specific anti-tumor immunity affect the 
outcome in patients with metastatic colorectal cancer?   
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5. Synopsis of publications included 
 
 
Paper I 
Protein kinase A antagonist inhibits -catenin nuclear translocation, c-Myc and COX-2 
expression and tumor promotion in ApcMin/+ mice. Cyclooxygenase (COX)-2 levels are 
elevated in most colorectal cancers (CRC) leading to local production of prostaglandin E2 
(PGE2) that has tumor-promoting properties. The benefits of using COX inhibitors in 
prevention of primary as well as recurring cancer are therefore currently discussed. While one 
effect of COX inhibitors is considered to be at the level of -catenin degradation in epithelial 
cells, other studies have also shown effects on angiogenesis and on anti-tumor immunity. 
With respect to control of -catenin degradation, the adenomatous polyposis coli (APC) gene 
which is the most commonly mutated gene in CRC, plays an important gate-keeping role in 
tumor formation and progression. APC is part of a destruction complex that phosphorylates 
and targets -catenin to proteosomal degradation. The destruction complex receives inhibitory 
signals both through the Wnt-Frizzled pathway and from PGE2 via the EP3 prostanoid 
receptor acting through PI3 kinase and protein kinase B. If not degraded, -catenin 
accumulates and translocates to the nucleus leading to expression of mitogenic and survival 
genes. However, in addition to the PGE2 mechanism of action through control of the 
destruction complex, it has recently been shown that protein kinase A (PKA) may directly 
phosphorylate -catenin at distinct sites which stabilizes and increases the nuclear activity of 
the protein [83]; and that PGE2 through cAMP and PKA may influence the stability of -
catenin via nuclear translocation in zebrafish stem cells [73]. This raises the question of 
whether COX inhibitors could have a second site of action in -catenin homeostasis in CRC. 
Here we used ApcMin/+ mice, a model where mice develop intestinal tumors due to defects in 
-catenin degradation and where the effect of COX-inhibitors on tumorigenesis is well-
established. We specifically inhibited the PGE2-cAMP pathway only at the level of PKA, and 
not through the destruction complex, by treating mice with Rp-8-Br-cAMPS, a PKA 
antagonist, for 6 weeks. This strategy was only possible as a different project with a spin-out 
company from the group could deliver gram quantities of this model compound which had 
also been subject to preclinical testing in animal experiments without any signs of toxicity. 
We show that treatment of mice with Rp-8-Br-cAMPS not only reduced tumor load but also 
specifically inhibited -catenin nuclear translocation and the activation of -catenin target 
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genes such as c-Myc and COX-2. This indicates that the direct regulatory effect of PKA on -
catenin nuclear translocation is operative in intestinal cancer, introduces a concept for -
catenin regulation in cancer and also goes directly into the discussion of use of COX 
inhibitors or aspirin in prophylaxis/secondary prophylaxis in colorectal cancer. 
 
Paper II 
Aggressive Treatment of Patients with Metastatic Colorectal Cancer Increases Survival. 
In this report, overall and disease-free survival was examined in a cohort of 239 patients with 
CRC and synchronous or metachronous liver metastases eligible for intentionally curative 
liver resection. The data have been stratified according to whether the patients received 
neoadjuvant chemotherapy, the number of resections and the surgical technique applied. 
Several centers have previously reported successful R0 resections after neoadjuvant 
chemotherapy to convert patients from inoperable to resectable status; however, little or no 
evidence is currently available on survival and oncologic outcome. Here, we report that 
patients with high tumor load that received neoadjuvant chemotherapy achieve oncologic 
results and life expectancy comparable to those that are primary resectable. The majority of 
patients with metastatic CRC to the liver experience disease recurrence and about 50% of 
these patients are available for re-resections. We report that the recurrences present with the 
same time interval after the primary tumor and subsequent metastases (11±1 months), and that 
the overall and disease-free survival after each resection is the same, the latter also reported 
by others. We interpret these findings in light of recent advances in tumor and metastasis 
biology and suggest that disease recurrence may represent parallel development of metastases 
that reach level of detection at different time points, rather than a progressing disease that 
rapidly acquires increased malignant and metastatic potential. In line with these results, we 
also observed a shift in target organs in later recurrences compared to early ones without 
affecting the clinical outcome, and that the presence of positive resection margins or presence 
of resectable extrahepatic disease at the time of the first liver resection did not have a negative 
impact on overall survival. These observations support emerging arguments for a new 
classification system in metastatic CRC. Although metastatic CRC has a poor prognosis, 
surgical treatment has clear patient benefit and strategies to make patients resectable and 
available for surgery should be pursued.  
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Paper III 
Regulatory T cell-mediated Inhibition of Anti-tumor Immune Responses is Associated 
with Clinical Outcome in Patients with Liver Metastasis from Colorectal Cancer. 
Surgical resection of colorectal metastases to the liver (CRLMs) is now offered to an 
increasing number of patients and neoadjuvant chemotherapy and new advances in surgical 
techniques further increases the number of patients with resectable disease. However, the rate 
of recurrence and mortality in patients after resection for CRLMs is still high. For the patients 
that die from rapid progressive disease within the first year after surgery, the procedure offers 
little benefit. On this background, tumor and immunological factors that predict or are 
associated with disease recurrence are important for patient selection and treatment strategy. 
Tumor-specific regulatory T cells play a significant role in suppressing anti-tumor immunity 
and negatively affect the prognosis. Based on findings in colorectal cancer, patients have a 
higher proportion of circulating regulatory T cells that suppress tumor immune responses, and 
inhibition of their activity may represent a future therapeutic avenue to improve anti-tumor 
immunity. Here, we examined whether tumor-immune responses are associated with the 
clinical outcome in patients undergoing liver resection for metastatic colorectal cancer. We 
found that the levels of regulatory T cell-mediated immune suppression of anti-tumor immune 
responses ex vivo at the time of surgery were more pronounced in patients with later recurring 
disease. Furthermore, regulatory T cell-mediated immune suppression could be perturbed by 
blocking the COX-2-PGE2-cAMP pathway and post-surgery PGE2 levels were also related to 
clinical outcome. Our findings could provide valuable prognostic information in these 
patients. 
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6. Discussion 
 
The incidence of colorectal cancer (CRC) is high and increasing worldwide. To excel at 
prevention, early detection and treatment of CRC, it is important to understand early steps of 
the tumor formation and be able to manage systemic aspects of the disease. An introduction to 
the field has been given in the previous. In the following, our results will be discussed with 
focus on how patients in the future may benefit from findings presented in the included 
publications.  
 
6.1 Connecting COX-2 and Wnt in colorectal cancer 
 
COX-2 is over-expressed in most CRCs compared to normal mucosa, and COX-2 cleaves AA 
to form PGE2. PGE2 is reported to have several local effects promoting the tumor growth in 
CRC; pro-angiogenic, anti-apoptotic and proliferative [64,170,171,188,189]. Furthermore, 
COX-2 expression contributes to maintaining a chronic inflammatory state in and around the 
tumor, thus leading to release of pro-inflammatory cytokines also with proliferative effects 
and shifting the tumor microenvironment towards an immunosuppressive dominance, which 
prevents an effective anti-tumor immunity.  
Wnt signaling is important in embryogenesis and cancer, and much insight to cancer 
biology has come from advances in the stem cell field. When a Wnt protein ligand binds the 
Frizzled receptor (member of the G protein-coupled receptors) the canonical Wnt pathway is 
switched to an “on” mode resulting in -catenin translocation to the nucleus where it interacts 
with the TCF/LEF transcription factor and thereby drives the transcription of genes important 
for cell proliferation and survival [120]. The main regulatory mechanism in the Wnt pathway 
is through limiting the availability of -catenin in the cytosol. The APC protein forms a 
complex with GSK3, CK-1 and Axin, the function of which is to phosphorylate -catenin at 
defined sites and thereby marking it for proteosomal degradation [160]. Wnt/Frizzled binding 
results in phosphorylation and activation of Dishevelled (Dsh/Dvl), a cytosolic protein, and 
activated Dsh/Dvl inhibits the ability of GSK3 to phosphorylate -catenin by poorly 
understood mechanisms [34].  
CRC has a natural history of transition from precursor to carcinoma that spans 15-20 
years, providing a window of opportunity for effective interventions and prevention [6]. Non 
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steroid anti-inflammatory drugs (NSAIDs) and aspirin are COX inhibiting agents, shown to 
protect against CRC development in several epidemiological studies [7] and may be 
beneficial in large population groups at risk [101]. Chemoprevention is a new emerging 
science which refers to the use of agents to inhibit, delay or reverse the carcinogenesis. In 
patients with the FAP syndrome, COX inhibition by NSAIDs can cause regression of existing 
colorectal adenomas and prevent formation of new polyps [195]. The protective effect of 
COX inhibition on colorectal tumor formation has also been reported in several animal 
studies. The discussion of whether these mechanisms could be used for clinical purposes in 
CRC patients is ongoing. One study reported 33-45% reduction in polyp recurrence rate in 
humans after intake of the selective COX-2 inhibitor celecoxib; however serious 
cardiovascular events were significantly more frequent in the treated group [19,154], and even 
more so with the COX-2 specific rofecoxib that was withdrawn from the market because of 
safety concerns [108]. Nonetheless, the US Food and Drug Administration have approved 
celecoxib for reducing adenoma frequencies in patients with FAP, a group at extremely high 
risk of developing carcinomas. As cardiovascular side effects may be a serious issue, these 
drugs are not recommended for primary protection of CRC. Aspirin and celecoxib have not 
been compared in randomized clinical trials [12,166]. Aspirin may, however, have an even 
larger protective effect and at the same time act cardioprotectively [168]. In addition, 600 mg 
aspirin given daily for more than 25 months to carriers of Lynch syndrome reduced the cancer 
incidence compared to placebo treatment in the first randomized controlled study to 
investigate primary chemoprevention with cancer as endpoint [32]. The chemopreventive 
effects of aspirin or NSAIDs in sporadic CRC need evaluation and further studies are required 
to establish the optimum dose and duration of treatment. Taken together, it may be that the 
ideal CRC chemopreventive agent remains to be discovered [7], although both aspirin and 
NSAIDs may be interesting; especially in secondary prevention, e.g. after surgery.  
While the correlation between COX and CRC has been known for some time, the 
molecular mechanisms responsible for the observed effects are only starting to be mapped 
out, (some of them introduced in the previous sections of this Thesis). In addition, COX-
independent mechanisms of NSAIDs and aspirin may also contribute to the protective effects 
on CRC including modifications of transcription factors such as NF-B and DNA 
stabilization [168]. Knowledge of COX-dependent as well as COX-independent mechanisms 
is important, as future chemoprevention relies on what molecular mechanisms that are 
dominant, and if drugs can be designed to avoid serious side effects. However, the COX-
independent mechanisms will not be discussed further here. 
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The COX-dependent molecular mechanisms involved have shown to be highly 
complex and several pathways are suggested as candidates. Recently PKA was suggested to 
be a possible link between the Wnt and COX-2-PGE2-cAMP pathway and based on previous 
experience in our lab with PKA signaling we found this interesting to pursue. Furthermore, 
we had gram quantities of the PKA inhibitor Rp-8-Br-cAMPS available due to a spin-off 
project from our lab.  
To date PKA has been suggested to interact at 
the level of GSK3, PKB and -catenin; all with the 
same net effect as activation of the Wnt signaling 
pathway (Figure 8). Phosphorylation of GSK3 at 
Ser9 was found to be a target for PKB located 
downstream of PI3K, however Ser9 at GSK3 is also 
shown to be substrate for PKA [56,113]. 
Furthermore, PKA can indirectly phosphorylate and 
activate PKB, which could provide an indirect 
mechanism for inhibition of GSK3 by PKA [59]. 
The result is inactivation of the kinase activity of 
GSK3, similarly to the effect of activation of the 
Wnt signaling pathway. In addition, PKA was 
recently shown to phosphorylate -catenin directly at 
two novel sites, Ser552 and Ser675 [83,186]. While there is agreement that phosphorylation at 
these sites does not affect regulation of the destruction complex and therefore is via non-
canonical mechanisms, there are contradicting reports regarding the effects on -catenin 
homeostasis. Two reports find that the PKA phosphorylation of -catenin affects stability and 
intracellular distribution [73,83] and one report states the opposite and offers a different 
mechanism of action via interaction with CREB-binding protein (CBP) [186]. Different 
experimental conditions may cause these discrepancies. 
Figure 8. PKA may interact with the Wnt
signaling pathway at multiple levels red circles
and cross. PKA can activate (indirectly
phosphorylate) PKB, inactivate (phosphorylate)
GSK3 or stabilize (phosphorylate) -catenin. 
In addition, non-PKA dependent mechanisms have also been suggested as interaction 
points between COX-2-PGE2 and Wnt signaling, which emphasize the complexity of the 
field. Loss of -catenin phosphorylation, and therefore loss of targeting the protein to 
proteosomal degradation, arises from the following: Inactivation of GSK3 or CK-1, 
mutations in the phosphorylation sites of -catenin or the inability of APC to enhance 
association with Axin [30]. In 2005, Castellone et al. used colon cancer cell lines and 
presented data suggesting that -catenin and the G subunit of the EP receptor bind the same 
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domain of Axin. Consequently, Axin-G binding results 
in displacement of APC and loss of phosphorylation of 
-catenin [38] (Figure 9). However, the authors used 
APC mutant cells in which the destruction complex is 
already compromised and all studies were done in vitro. 
In addition, PKB may be able to phosphorylate -catenin 
directly, representing yet another non-canonical 
mechanism [183]. In a more recent study, the authors 
used zebrafish to study PGE2/Wnt interactions in 
hematopoietic stem cells (HSC) in vivo and proposed 
activation of PKA as a functionally significant effector 
downstream of PGE2 [73]. The differences could be 
caused by different experimental conditions, in vivo 
versus in vitro and from studying HSC with a functional 
APC protein versus CRC cancer cells with an APC 
mutation. 
Figure 9. Non-PKA specific PGE2/Wnt
interactions mediated by Axin displacement
and PKB specific phosphorylation of -
catenin. 
In Paper I, we show that PKA specific phosphorylation of -catenin at Ser552 and 
Ser675 was reduced after PKA inhibition in HCT-116 cells, a human colon cancer cell line. In 
ApcMin/+ mice, animals predisposed to develop intestinal tumors, treatment with the same 
antagonist reduced the size of the tumors by 36% compared to vehicle-control treated 
animals. This could be explained by the finding that PKA specific phosphorylation stabilizes 
-catenin in the cytosol and facilitates nuclear translocation (Figure 10). Nuclear translocation 
of -catenin is a prerequisite for activation of TCF/LEF-mediated transcriptional activation, 
which is also evident from the finding that PKA antagonist-treated animals expressed less 
COX-2 and c-Myc which both are expressed upon TCF/LEF transactivation (Paper I).  
Treatment with indomethacin reduced the number and size of the lesions to a greater 
extent than the PKA antagonist, and the fact that the indomethacin-treated animals had almost 
no intestinal tumors precluded us from studying the tumors from these mice by 
immunohistochemical methods. The difference between COX and PKA inhibition could be 
explained by the fact that indomethacin is located upstream and thereby could mediate effects 
also via the PGE2-EP3-PI3K-PKB pathway. However, in the colon cancer cell line, the effect 
of indomethacin did not differ from the effects of Rp-8-Br-cAMPS with respect to PKA 
specific phosphorylation, c-Myc expression was, in fact, reduced even more after Rp-8-Br-
cAMPS treatment, a finding that indicates that other mechanisms may cooperate to mediate 
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anti-tumorigenic effects of COX inhibition in the CRC animal model in vivo, i.e. 
angiogenesis, immunology or other important proliferative or apoptotic pathways.  
 
 
 
Figure 10. Inhibition of COX-2 upstream by indomethacin and PKA downstream by Rp-8-Br-cAMPS in CRC cells and in a 
CRC animal model.  
 
In conclusion, treatment of a well-established mouse model of human CRC and FAP 
with a PKA antagonist not only reduces tumor size but also inhibits -catenin nuclear 
translocation and the activation of -catenin target genes such as c-Myc and COX-2. This 
indicates that the direct regulatory effect of PKA on -catenin nuclear translocation described 
in cell lines and HSC is also operative in intestinal cancer. 
 
6.2 Improving treatment of systemic colorectal cancer 
 
The incidence of CRC is increasing in many countries [35], consequently more patients will 
present with synchronous or metachronous metastases. The liver (CRLM) is the main organ 
for metastatic disease from CRC, and may be the main obstacle to cure a large group of 
patients [45]. For the past 20 years there has been a great development in CRLM treatment. 
While only 10% were assessed as resectable and consequently curable 10 years ago, 20-25% 
are today surgically treated with the intent to cure [146]. It is important to constantly 
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challenge the treatment strategies and disease perception regarding this patient group. 
Metastatic disease was considered equivalent to incurable status just a few years ago. 
However, with the treatment options of today, even patients with extensive disease upon 
presentation may prove to be long-time survivors. Furthermore, even though cure cannot be 
achieved in many, converting the cancer from rapidly progressing disease and death to a slow 
progressing or a “chronic state” of disease can improve the quality and time of survival in 
those that are not curable.  
It is a problem to get good data regarding the natural course of patients with untreated 
liver metastasis as studies would be unethical with respect to currently available treatment 
options. However, old reports indicate that the survival is short (<6 months) as discussed in 
the previous [16,111]. Today, patients with non-resectable CRLM have an increased expected 
survival thanks to modern chemotherapy and other adjuvant treatment options such as RFA 
[70]. Furthermore, bowel resection followed by chemotherapy appeared to be a better option 
than chemotherapy alone in patients with CRC and unresectable synchronous CRLM, as 
shown in an non-randomized trial [66]. The expected 5-year survival after resection for 
CRLMs is 35-50%. After neoadjuvant downsizing followed by resection of the CRLMs the 
survival is reported to be comparable 33-50% [70]. This is in line with our results, showing 
that patients receiving neoadjuvant chemotherapy to downsize the tumor load reached an 
overall long-term survival comparable to that of primary resectable patients. Furthermore, 
neoadjuvant chemotherapy serves indirectly as a tool for selection of patients with the best 
prognosis after surgical resection, as patients that progress during ongoing treatment will 
probably not benefit from surgical treatment. These results support an aggressive treatment 
approach to metastatic CRC which also has been suggested by others [2,5,135,150]. 
 Oslo University Hospital has moved from a small to a medium volume center with 
respect to number of resections performed on CRLM. New treatment strategies applied to this 
patient group to improve treatment and consequently the survival, includes neoadjuvant and 
adjuvant chemotherapy, two-stage surgery with portal vein embolisation, laparascopic 
surgery, surgical techniques adapted from liver transplantation, techniques and surgical tools 
to limit the blood loss, radio frequency ablation and re-resections for disease recurrence. In 
Paper II we present data from a time period where most of these strategies were implemented 
as treatment options for patients with CRLM. We compare outcome with respect to overall 
and disease-free survival in different subgroups based on established risk factors and the new 
modalities. The material is based on 239 patients with resectable liver metastasis and even 
though this is a large single-centre study in Norway, it is a small cohort when doing 
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comparisons between subgroups. The heterogeneity of the disease and between patients is 
another problem when performing registrations and doing statistics. Nonetheless, despite 
shortcomings, we believe our material is interesting with respect to ongoing discussions 
regarding treatment of CRLM. 
 We report that a second and third resection of recurring CRLMs should be considered 
when possible because the survival is the same after each resection and our results point in the 
direction that resection also should be assessed in patients with extrahepatic recurrences. 
Extrahepatic metastatic spread has previously been considered an end-stage-disease. In recent 
years, combined liver and lung resection have produced long-time survivors. Six patients 
presented with concomitant liver and lung metastases in the material presented in Paper II and 
only one of them died of progression of the lung manifestation that could not be handled 
surgically. It is also interesting to observe that patients resected for recurrent disease of the 
lung after first having been subjected to hepatic resection, had comparable and maybe even 
better survival compared to those repeatedly resected for recurrent disease of the liver. 
Consequently, pulmonary metastasis alone should probably no longer be considered an 
exclusion criterion for surgery [37]. The same could also be the case for non-pulmonary 
extrahepatic disease, as long as it is resectable or may become resectable after downsizing. 
 If the resection margin after resection for CRLM contains tumor cells, the disease is 
by definition not cured and impaired outcome should be expected. Furthermore, the distance 
of the free margin is reported to be important as a resection margin of 1 cm or more confers a 
survival advantage over subcentimeter negative margins [47]. However, accumulating data 
suggesting adjuvant chemotherapy may change the perception of survival after R0 versus 
R1/R2 resections, and this is important as it allows more patients to undergo resections with 
curative intent [10,46]. Chemotherapy and repeated resections may help to explain why the 
discrimination between R0 and R1/R2 resections of CRC metastases is not crucial with 
respect to overall survival in our material as in other studies [10,46]. 
Eight different scoring systems for predicting disease-specific survival after resection 
for CRLMs were presented in the Introduction [60,86,94,123,128,137,157,208]. These 
systems have proven clinically relevant with respect to survival, but have not been used for 
risk stratification in areas such as patient selection, administration of chemotherapy or 
surveillance programs. Furthermore, the data in these reports are from patients who 
underwent resection from 1968 to 2005. The field has evolved significantly since then and the 
predictive scores do not account for advances in operative techniques and adjuvant therapies. 
One problem, for example, is how to score with respect to disease extent as more patients are 
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receiving neoadjuvant downsizing chemotherapy. Gomez & Cameron recently suggested in 
their review that there is no ideal prognostic scoring system [75]. In conclusion, one must be 
careful when using scoring systems for clinical purposes. Patient selection is important and 
has been a great challenge. Clinical parameters may be nothing more than indirect 
measurements of tumor biology and tumor microenvironment, and therefore not suitable for 
patient selection purposes.    
A brief introduction to CRC tumor biology was given in the previous sections. 
Chromosomal instability, mutations in K-ras and Tp53 and tumors expressing high levels of 
CEA are all associated with poor prognosis [45]. Nuclear -catenin overexpression may be 
associated with the ability of the cancer cells to metastasize [40]. In the near future scoring 
and prognosis estimation of CRC will probably include standardized sets of molecular 
classifications, tumor immunologic markers and microenvironmental factors in a larger 
degree than today. A French group reported that type, density and location of immune cells in 
CRC may have higher predictive power than prognosis estimated by the conventional AJCC-
TNM histological classification [68]. In addition, survival following hepatectomy for 
colorectal metastases should not be considered an isolation of the primary CRC pathology, as 
tumor cells populating distant organs may continue to evolve and gain different genetic 
background and the tumor microenvironment may differ from that of the primary tumor [60]. 
 
 
 
Figure 11. Parallel development of primary cancer and metastasis in CRC. Cancer cells may metastasize at an early time 
point and cells metastasizing at late time points may not be as capable as those at early time points to infiltrate and populate 
distant organs. 
 
Two different models of systemic cancer are accounted for; the linear progression 
model, in which the primary tumor is the engine of cancer progression and the development 
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of fully malignant cells occurs locally and they are released at a late time point; and the 
parallel progression model, where the primary tumor at an early time point releases 
disseminating tumor cells capable of reaching different target organs and developing into 
metastases at these sites (Figure 11) [98,181]. The cells may also be released at slightly 
different, but still early, time points with different mutational backgrounds giving them 
homing properties specific for different target organs. 
Studies designed to describe tumor growth in primary tumor and metastases show that 
metastases most often grow at the same rate as primary tumors and seldom at more than twice 
the speed of the primary tumor [62]. Most of these studies are done in breast cancer, showing 
that a primary cancer uses 12 years to reach a size where it is clinically recognizable and the 
metastases consequently use 6-12 years to develop to a clinically identifiable size, taking into 
account the indicated growth rate. If these findings are correct, it would implicate that the 
disseminating tumor cells would have left the primary cancer at an early time point in patients 
with synchronous disease having larger metastases than the primary tumor. 
A common perception of the linear model is that the disease progresses and acquires 
more aggressive biological features at later disease stages. However, the parallel model opens 
for a different interpretation. If the metastasizing process occurs at an early time point in the 
development of the primary tumor, the disease may not progress and become more aggressive 
at later stages. The primary tumor may possess more aggressive metastasizing properties early 
in development rather than late. And the primary tumor and the metastases may develop in 
parallel, gain different mutations and due to different growth conditions in various tissues be 
more or less aggressive than the primary tumor [98,181]. Hypothetically, in the parallel 
model, all the metastases that eventually will present are already present at the time of 
diagnosis. Metastases in various organs may be manifestations of a process that has taken 
years to reach the level of detection, and as such, metastases may not be a sign of an explosive 
metastatic spread [178]. In Paper II we report mean time intervals from primary tumor to liver 
metastasis and from liver metastasis to presentations of recurrences in patients with resectable 
CRLM. The disease-free intervals between each event are the same, and even though this is 
not firm evidence of the disease not becoming more aggressive, it is an interesting finding.  
Another interesting issue is the ability of the metastasis to spread beyond its first 
implantation site. Hypothetically, the metastases that will present are there already at 
resection of the primary tumor. Thus the patient may actually have a better chance of cancer-
specific survival after removal of every “new” disease recurrence as this may not represent 
new disease, but the last remaining. In line with this thinking, “recurrent disease” may be a 
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misnomer as the disease may not be recurring, but continues to deliver earlier established 
metastases growing in parallel and reaching a size that allows diagnosis at different time 
points following the primary surgery. Thus, resection of metastases may in many cases 
represent incremental tumor-reductive surgery rather than treatment of recurrent disease. 
In reality it is likely that metastases develop on both a linear and a parallel scale and that 
metastatic disease is systemic or multifocal in its nature and may encompass unrecognized 
foci at the time of surgery in most patients irrespectively of the presentation at diagnosis. 
Eradication of all tumor tissue may therefore not be conceivable in the majority of the 
patients. However, this recognition should not preclude an aggressive treatment approach to 
induce resectable patients and perform repeated resections that continue to reduce tumor load.  
 
6.3 Treg cancer immunity in liver metastasis from colorectal cancer 
 
To investigate possible prognostic and predictive parameters for use during the assessment 
and treatment of patients with CRLM, we examined whether immune responses are 
associated with the clinical outcome. We found that Treg-mediated immune suppression at 
the time of surgery was more pronounced in patients with later recurring disease. 
The frequency of Tregs is increased in blood from CRC patients compared to healthy 
blood donors [42,117,200]. Depletion of Tregs from the blood of CRC patients unmasks 
CD4+ and CD8+ T cell responses towards tumor antigens or tumor associated-antigens 
[42,206]. Tumor infiltrating CD3+, CD8+ and CD45RO+ T cells are associated with improved 
prognosis in many cancers including CRC. The opposite is observed with tumor infiltrating 
Tregs, as high density of Tregs associates with poor outcome in many cancer forms. These 
findings led to the hypothesis that Tregs infiltrating CRC also are associated with poor 
outcome. However, conflicting and surprising data have accumulated in CRC in which high 
Treg infiltration in recent studies is reported to be associated with improved survival 
[61,138,163]. The reports are based on immunohistochemistry on sections of tumors and 
FOXP3 is used as a Treg marker. However, functional data are missing in most of these 
reports. Concluding that infiltrating FOXP3+ T cells are protective in CRC before the cells are 
shown to be functionally suppressive could be a mistake. Other T cells (CD8+CD25+FOXP3+ 
T cells and CD4+CD25+FOXP3+ effector T cells) may express some level of FOXP3. 
However, in one study CD4+FOXP3+ sorted cells from CRC tumor tissue had the capacity to 
suppress T cell proliferation and IFN production by effector T cells [102]. In another, 
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CD4+CD25+ Tregs were reported to induce regression of intestinal tumors in ApcMin/+ mice 
[55]. The two latter add functional data supporting the hypothesis that Treg infiltration in 
CRC may potentially be beneficial.   
The immune system is designed to treat infections caused by bacteria, virus and fungi, 
most of which are infections that last for 3-5 days. After the foreign pathogen is eradicated, 
the effector T cells may change phenotype and become Tregs expressing FOXP3 to take 
down excessive immune activity. The high FOXP3+ Treg frequency associated with improved 
survival in CRC may be a consequence of high frequency of infiltration of previous effector T 
cells, rather than the suppressive properties of the Tregs at the time of investigation. 
Furthermore, in a chronic inflammatory state, high activation would need high suppression to 
balance the response. As high CD8+ T cell density correlates with high infiltration of FOXP3+ 
T cells in CRC [163], the CD8 response may weigh heavier than the suppressive function of 
the Tregs. Human Tregs may also express cytotoxic molecules such as perforin and granzyme 
and could in this way induce death of cancer cells [76], but the direct effect of Tregs on 
cancer cell still remains to be characterized.  
The colon and rectum are highly populated with bacteria which, under normal 
conditions are kept in the lumen by a monolayer of epithelial cells linked together by tight 
junctions. This defense is impaired in CRC and bacteria translocate from the lumen to the 
tissue leading to local inflammation with the release of pro-inflammatory cytokines. The pro-
inflammatory cytokines act tumor-enhancing and pro-angiogenic through activation of 
transcription factors like NF-B or STAT3 [175]. Thus, by suppressing inflammation and 
immune responses resulting from bacterial invasion, FOXP3+ Tregs could in fact be anti-
tumorigenic in CRC. This could explain a relationship between FOXP3+ T cell abundance 
inside the tumor and favorable prognosis in CRC (Figure 12).  
We focused our work on peripheral immunology and studied Treg mediated anti-
tumor responses in blood versus outcome in patients with resectable CRLM. Our main finding 
was that Treg inhibition of anti-tumor activity was more pronounced in patients that later 
presented with recurrent disease suggesting that Tregs may affect the clinical course of 
metastatic CRC. Furthermore, our data suggest that Tregs express COX-2 and that one 
important mechanism by which they suppress surrounding effector cells is by perturbation of 
the COX-2- PGE2-cAMP-PKA pathway. PGE2 plasma levels were related to disease activity, 
but did not decline as rapidly as expected after surgery, suggesting that COX-2 may be 
expressed by other sources than the cancer cells and Tregs may be a substantial contributing 
factor. The study presented in Paper III involved a small cohort of patients (n=18) and some 
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were lost from follow-ups as they died or were otherwise prevented from meeting. The group 
was split 18 months post-operatively into a disease-free and a recurrent disease group. We 
checked for group-differences regarding tumor size, number of metastasis, chemotherapy, sex 
and age as it is possible that the anti-tumor immune function is determined by the extent of 
the disease at the time of surgery, but we were not able to identify such correlation in the 
cohort.  
 
 
Figure 12. During the course of an infection (top) the immune response balances activation to fight foreign pathogens and 
suppression to reduce the response when a pathogen has been eradicated preventing autoimmunity. Lymphocyte infiltration 
in CRC (bottom) could relate to foreign pathogen invasion as well as antigens originating from the tumor cells. An 
inflammatory response towards microbes with the release of pro-inflammatory cytokines may be unwanted as it may promote 
tumor growth. However, an inflammatory response targeting the cancer cells may be beneficial. Tregs serve as breaks in both 
of the described mechanisms and may therefore possess both tumor-suppressive and tumor-promoting effects in primary 
CRC which could explain conflicting reports.  
 
A quality of our study that distinguishes it from many other Treg-cancer studies is the 
temporal aspects, as we followed the patient over time post-surgery and have thereby samples 
from different disease-stages. This allowed us to use each patient as its own control. The most 
interesting time-related finding was the observation that PGE2 levels related to disease 
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activity. Furthermore, that FOXP3+ Tregs in patients with recurrent disease expressed higher 
levels of COX-2 than in the disease-free patients, which may be a sign of activation. Lastly, 
the activation marker CD69 was up-regulated in CD4+ T cells in patients with active disease 
at follow-ups compared to disease-free patients.  
Another asset in our study of Treg-mediated effects in CRLMs is that we included and 
based our findings on functional data and not exclusively on phenotypical data. A challenge 
when studying cancer specific anti-tumor immunity is that the expected effects on cytokine 
production or proliferation are very low, as compared to the massive response to pan-clonal 
stimulation with anti-CD2/CD3/CD28 beads or staphylococcal enterotoxin B (SEB). 
Furthermore, the HLA-specificity of the tumor-associated antigens (CEA peptides) used to 
trigger an immune response has been discussed. We found that 2 of 9 patients with recurrent 
disease and 6 of 7 patients that remained disease-free were HLA-A2 positive. If the peptides 
were HLA-A2 restricted, this could implicate that patients with recurrent disease do not 
respond to CEA stimulation and our results would be based on failure of stimulation rather 
than the suppressive effect of the depleted Tregs. However, the peptides we used have been 
reported to have preference, but not restriction, to HLA-A3 [95] and HLA-A24 [139] (for 
 reported to be HLA-A2 restricted. Indeed, 
we observed that these two peptides in our 
earlier study [206] appeared to give good 
responses in all patients independently of 
HLA status. Furthermore, in Figure 13 we 
showed that TNF and IFN responses to 
CEA-peptide stimulation in PBMC and 
Treg-depleted PBMC stratified on HLA-
A2 status, revealed no significant 
differences upon Treg depletion, although 
there is a tendency for basal levels to be 
higher in HLA-A2 negative patients.  
Cancer vaccines are currently being tested for many forms of 
CEA61-69 and CEA318-327, respectively) and are not
cancer. The concept is to 
trigger 
Figure 13. Cytokine responses in HLA-A2 positive and HLA-
A2 negative individuals after stimulation with CEA peptide in
PBMC (black bars) and Treg depleted PBMC (grey bars). 
a cancer-specific immune response to provide a maximal attack of the tumor cells. One 
challenge is to identify immunogenic target molecules and several candidates have been 
suggested and are currently entering controlled clinical trials. So far, results from cancer 
vaccine trials have reported promising results [127] and synergistic effects can be expected if 
vaccine is given in combination with chemotherapy [155]. Furthermore, vaccines are safe and 
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administrable. If we could manipulate the regulatory pathways (e.g. Tregs) of the immune 
system, this could provide further beneficial effects for patients subjected to vaccination. A 
problem with CRC when developing immune based therapy is that CRC is not as 
immunogenic as for instance melanoma, which expresses several tumor-associated antigens 
(TAA) resulting in a strong immunological response to the tumor. In CRC, p53, CEA, Her2 
and heparanase have been proposed as antigen targets [23]. In recent years the surface marker 
CD55 and the surface glycoprotein oncofetal antigen 5T4 have been found to be expressed by 
human adenocarcinoma and may therefore constitute good targets for vaccine development 
[144].   
In conclusion, regulatory T cells protect many cancers from anti-tumor immune 
respons
6.4 Perspectives 
 Paper I, we discovered that PKA inhibition affects tumor formation in a CRC animal model 
ighlight the effect of implementation of novel treatment strategies with 
respect to disease-free and overall survival in patients directly subjected to liver surgery or 
es and may help the tumor cells to evade detection by the immune system. This 
information can be used and may provide valuable prognostic information. A more complete 
understanding of Treg function and suppressive mechanisms should be persued and will in the 
future hopefully allow us to modulate the immune response to an optimal defense.  
 
 
In
and this goes directly into the discussion regarding COX inhibition in human CRC and FAP. 
COX inhibition was far more tumor-reductive than PKA inhibition alone in the ApcMin/+ mice. 
Protein kinase A phosphorylation of -catenin is therefore probably only one of many 
mechanisms responsible for the effect on tumor load. Future research should focus on 
mapping yet other molecular pathways responsible for the COX-associated effects. The next 
step would be to develop drugs directly targeting these pathways and thereby increase 
beneficial effects and, if possible, at the same time avoid dangerous side effects. In addition, 
use of different NSAIDs should be evaluated further. PKA is a common messenger for PGE2 
in all cells, not exclusively in cancer cells, and other effects of perturbation of the PGE2-
cAMP-PKA pathway would have to be addressed if this target is to be pursued. Furthermore, 
APC mutation is only one out of many mechanisms responsible for progression towards CRC 
development, and PKA inhibition would therefore also have to be tested in cancers where the 
APC protein is intact. 
In Paper II we h
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after d
CRLMs. However, the mechanisms of how Tregs suppress 
bystand
ownsizing to resectable CRLMs. We address the question of whether neoadjuvant 
chemotherapy works, whether re-resection is indicated, and how extrahepatic disease should 
be assessed. Whether the oncologic outcome after laparascopic surgery equals that of open 
surgery and what benefits we get from clinical scoring systems. Furthermore, we discuss the 
validity of using predictive variables based on old patient materials on today’s patients. Our 
report adds arguments to ongoing discussions in the field, however, it cannot be used to 
develop guidelines, as that would have to be based on randomized clinical trials. Furthermore, 
the search for novel biologics and chemotherapeutics as well as improving the overall 
treatment from disease detection to surgery must continue. Personalized medicine will 
continue to evolve, and the discovery of new tumor-specific molecular signatures could open 
new avenues of drug targeting.  
In Paper III we suggest that Tregs, a suppressive T cell subset, may affect the course 
of the disease in patients with 
er T cells, B cells and NK cells are far from fully understood. Ongoing projects in our 
lab are aiming to discover a main suppressive function; if such a mechanism exists it could be 
a potentially important drug target.  In a recent project, we found that Tregs maintain their 
suppressive function after fixation, but not after trypsination, indicating that a cell-surface 
protein is directly involved. Furthermore, conventional T cell inhibitors do not affect Treg 
activation, indicating pathway redundancy or that Treg activation proceeds by distinct 
signaling mechanisms. Finally, Tregs suppress effector cells in a time window of immune 
suppression [77]. The significance of TILs in CRC is controversial and in need of further 
characterization. One possibility could be to study Treg infiltration in CRC and synchronous 
CRLM, the latter being an environment shielded from the bowel microflora. Tregs affect 
other immune cells such as T cells, B cells and NK cells and are thereby thought to affect 
cancer development and progression. However, it would also be interesting to study potential 
effects of Tregs on cancer cells directly. Immune cell homing mechanisms could serve as 
drug targets and if we can identify molecular mechanisms that are unique for Tregs versus 
effector T cells, this could be used to modulate the tumor microenvironment to help us in the 
fight against cancer progression.  
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7. Conclusions 
 
 
1. a)  Treatment with a PKA antagonist decreased the size of intestinal tumors in ApcMin/+ 
mice, an animal model of human FAP and CRC, suggesting that one of the beneficial 
effects of COX inhibition in CRC is through perturbation of the PGE2-cAMP-PKA 
pathway, as PKA is located downstream of EP2/4, but not EP3.  
b) Our data suggest that the mechanism of action is at the level of -catenin 
phosphorylation and subsequent cytoplasmic accumulation and nuclear translocation. 
 
 
2. a) Patients with high tumor load of CRLMs receiving neoadjuvant chemotherapy achieve 
oncologic results and life expectancy comparable to those that are primary resectable with 
low tumor load, indicating that pre-operative chemotherapy may be beneficial to these 
patients.  
b) Patients with resectable recurrent CRLM have the same estimated survival as after the 
first resection. The recurrences present with the same time interval after the primary tumor 
and subsequent metastases, indicating that recurrent disease may not be a sign of 
explosive fast progressing metastatic disease. 
 
 
3. a) Tumor-associated antigen-specific CD4+CD25+CD127lowFOXP3+ regulatory T cells 
with suppressive properties can be identified in blood from patients with CRLM.  
b) Patients with CRLM and high levels of Treg mediated anti-tumor immune suppression 
in peripheral blood have increased risk of disease recurrence compared to patients that 
have low levels of Treg suppression.  
c) Tregs appeared to suppress through COX-2-PGE2 dependent mechanisms, PGE2 
plasma levels correlated with disease progression in metastatic CRC and Tregs may be a 
source of PGE2 in these patients.  
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Protein kinase A antagonist inhibits b-catenin
nuclear translocation, c-Myc and COX-2
expression and tumor promotion in ApcMin/+ mice
Kristoffer W Brudvik1, Jan E Paulsen2, Einar M Aandahl1,3, Borghild Roald4 and Kjetil Taskén1*
Abstract
Background: The adenomatous polyposis coli (APC) protein is part of the destruction complex controlling
proteosomal degradation of b-catenin and limiting its nuclear translocation, which is thought to play a gate-
keeping role in colorectal cancer. The destruction complex is inhibited by Wnt-Frz and prostaglandin E2 (PGE2) - PI-
3 kinase pathways. Recent reports show that PGE2-induced phosphorylation of b-catenin by protein kinase A (PKA)
increases nuclear translocation indicating two mechanisms of action of PGE2 on b-catenin homeostasis.
Findings: Treatment of ApcMin/+ mice that spontaneously develop intestinal adenomas with a PKA antagonist (Rp-
8-Br-cAMPS) selectively targeting only the latter pathway reduced tumor load, but not the number of adenomas.
Immunohistochemical characterization of intestines from treated and control animals revealed that expression of
b-catenin, b-catenin nuclear translocation and expression of the b-catenin target genes c-Myc and COX-2 were
significantly down-regulated upon Rp-8-Br-cAMPS treatment. Parallel experiments in a human colon cancer cell line
(HCT116) revealed that Rp-8-Br-cAMPS blocked PGE2-induced b-catenin phosphorylation and c-Myc upregulation.
Conclusion: Based on our findings we suggest that PGE2 act through PKA to promote b-catenin nuclear
translocation and tumor development in ApcMin/+ mice in vivo, indicating that the direct regulatory effect of PKA
on b-catenin nuclear translocation is operative in intestinal cancer.
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Findings
The adenomatous polyposis coli (APC) gene is thought to
play a gate-keeping role in the tumor formation and pro-
gression and is the most commonly mutated gene in all
colorectal cancers. In humans, APC mutations can be
acquired (spontaneous CRC) or inherited as in the auto-
somal, familiar adenomatous polyposis (FAP), character-
ized by the formation of multiple colonic adenomatous
polyps [1]. Inactivation of both APC alleles (APC-/-) is
considered necessary for tumor formation. The APC pro-
tein forms a destruction complex with Axin, glycogen
synthase kinase 3b (GSK3b) and casein kinase 1 (CK1)
which phosphorylates b-catenin at multiple sites [2], and
targets b-catenin for ubiquitination and to degradation
by the proteasome system [3]. A defective APC protein
leads to cytoplasmic accumulation and translocation of
b-catenin to the nucleus [4]. b-catenin, originally discov-
ered as a cadherin-binding protein, has been shown to
interact with and function as a coactivator of T-cell fac-
tor/lymphocyte enhancer factor (TCF/LEF) transcription
factors. Human transcription factor 4 (hTCF-4), a TCF
family member that is expressed in human colonic
epithelium and colon carcinoma cells, transactivates tran-
scription only when associated with b-catenin [5]. The
result is expression and production of mitogenic and sur-
vival genes including c-Myc [6], cyclin D1 [7] and
cyclooxygenase-2 (COX-2) [8].
COX-2 levels are elevated in as many as 85% of human
CRCs and approximately 50% of colorectal adenomas [8].
Studies have shown that COX inhibition by non-steroidal
anti-inflammatory drugs (NSAIDS) or aspirin reduces the
risk of CRC and may be beneficial in large population
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groups at risk [9]. Selective COX-2 inhibitors are also
associated with a decline in the incidence of CRC and
reduced mortality rate, although COX-2 inhibitors have
been associated with serious cardiovascular events in this
context [10]. Prostaglandin E2 (PGE2) has been shown to
be an important mediator of COX-2 associated effects,
and PGE2 levels are elevated in CRC biopsies compared
with normal mucosa and even in patient blood samples
[11]. Beside an anti-angiogenic effect [12], COX inhibi-
tion promotes apoptosis and alters tumor growth [13].
PGE2 and COX-2 over-expression also correlates with
CRC risk and metastasis of CRC [14], making this path-
way relevant also in follow-up after treatment of the pri-
mary cancer. Furthermore, our observations show that
the PGE2 produced also inhibits anti-tumor immunity
through the EP2 prostanoid receptor - cAMP - protein
kinase A (PKA) - Csk pathway in effector T cells that
inhibit T cell activation [11].
Both the Wnt-Frz and the PGE2-EP3 pathway acting
through phosphoinositide 3-kinase (PI3K) and protein
kinase B (PKB) negatively regulates the APC destruction
complex that controls b-catenin proteosomal degrada-
tion. COX inhibitors are thought to reverse the inhibitory
effect of PGE2-EP3 receptor signaling on the APC
destruction complex promoting b-catenin degradation
and reversing the mitogenic effects. However, homozy-
gous deletion of the gene for the PGE2 receptor EP2 also
reduced the number and size of colorectal polyps in a
polyposis mouse model [15]. Furthermore, recent reports
have shown that PKA can phosphorylate b-catenin at
Ser552 [16] and Ser675 [16,17] and that the effect of b-
catenin phosphorylation at the latter site is mediated by
non-canonical mechanism(s) that does not involve regu-
lation of the formation of the destruction complex.
While Taurin et al. show that Ser675 phosphorylation
promotes b-catenin interaction with the transcriptional
coactivator CREB-binding protein in the nucleus and
does not affect b-catenin stability and intracellular loca-
tion [16], Hino et al. report that PKA phosphorylation of
the same site stabilizes b-catenin and affects its intracel-
lular localization [17]. These differences highlight the
complexity of regulation of Wnt-b-catenin signaling and
may relate to the experimental conditions and system
examined. Finally, PGE2 has been shown to control b-
catenin homeostasis in zebrafish stem cells by signaling
through both the EP3 receptor to the destruction com-
plex and through the EP2 and EP4 receptors via cAMP
to PKA affecting b-catenin stability [18]. Given the
importance of b-catenin as a trans-activator in CRC and
the interest in COX chemoprevention, the question of
whether the PGE2-EP2/4-cAMP-PKA pathway is also
active in controlling b-catenin levels in CRC is highly
relevant [19].
The ApcMin/+ mouse is a well-established model of FAP
with a germline mutation in one APC allele, thus increas-
ing the probability of a double allele mutation and tumor
formation. ApcMin/+ mice develop multiple adenomas in
the intestinal tract, mainly in the small intestine, at an
early age which can be blocked effectively by COX inhibi-
tion through NSAIDS. Here, we asked whether perturba-
tion of the EP2/4 but not the EP3 pathway by inhibition at
the level of PKA, could affect b-catenin levels and tumor
formation. We show that treatment of ApcMin/+ mice with
a PKA antagonist, Rp-8-Br-cAMPS, reduces tumor load,
b-catenin levels and nuclear translocation as well as
expression of b-catenin target genes in ApcMin/+ mice
in vivo.
Differential effects of COX and PKA inhibition on tumor
formation in ApcMin/+ mice
To more closely delineate the effect of PKA in the COX-2
- PGE2 pathway active in colorectal cancer, we treated
ApcMin/+ mice with the PKA antagonist Rp-8-Br-cAMPS
for 6 weeks using earlier established doses (see Additional
file 1, Supplementary information) and compared the
result with that of treatment with the COX inhibitor indo-
methacin, previously shown to inhibit tumor development
in the ApcMin/+model [20]. Phosphate buffered saline
(PBS) was used as vehicle control for the Rp-8-Br-cAMPS.
Examination revealed that indomethacin reduced the
number and area of tumors in the small intestine of the
ApcMin/+ mice compared to PBS (from 47 to 3 tumors per
mouse and from 0.44 mm2 to 0.10 mm2 tumor area; P <
0.001; Figure 1A, B). The PKA antagonist Rp-8-Br-cAMPS
did not significantly reduce the number of adenomas (47
versus 43 tumors; P = 0.368, Figure 1A, B), but reduced
the tumor area by 36% (from 0.44 mm2 to 0.28 mm2; P <
0.001; Figure 1). Specifically, tumor load was reduced in
the distal part of the small intestine (Figure 1C). The dif-
ferential effect of COX inhibitor and PKA antagonist on
tumor numbers and tumor size indicated to us that the
mechanisms of action could be distinct and were exam-
ined in more detail in the following.
Inhibition of PKA does not affect lymphocytic tumor
infiltration or HIF-1a expression in ApcMin/+ mice tumors
Lymphocytic tumor infiltration affects the course of
human CRC where type, density and location of immune
cells are shown to have higher prognostic power than the
classical UICC-TNM staging [21]. Furthermore, the
hypothesis of adaptive regulatory T cells (Treg) inhibiting
anti-tumor immune responses has been subject to consid-
erable interest [22]. Previously, we found that upon activa-
tion, Tregs express COX-2 and suppress effector T cells
by PGE2 - cAMP dependent mechanisms that may be of
clinical relevance in patients with CRC [11]. However,
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immunohistochemical characterization of small intestinal
tumors from PKA antagonist Rp-8-Br-cAMPS treated ani-
mals did not reveal any significant changes in the number
of CD3+ T cells, CD8+ cytotoxic T cells, Foxp3+ Tregs or
CD56+ natural killer (NK) cells (Figure 2A, B and Addi-
tional file 2, Figure S1). In contrast, levels of granzyme B
(GZMB), a protein expressed in the cytotoxic T lympho-
cytes (CD8+ T cells) and NK cells, were reduced in Rp-8-
Br-cAMPS treated animals which may indicate more
degranulated cytotoxic cells post activation (Figure 2B).
Our observations indicate that intestinal immune
responses play a minor role in the development of the
ApcMin/+ mice tumor load, consistent with other observa-
tions [23].
PGE2 also affects angiogenesis and up-regulates vascular
endothelial growth factor receptor-1 (VEGFR-1) in a
human colon cancer cell line [12] whereas indomethacin
inhibits the expression of VEGF and thereby angiogenesis
[24]. To assess treatments effects on angiogenesis, we
examined levels of the hypoxia-inducible transcription fac-
tor (HIF)-1a which regulates the expression of target
genes important in angiogenesis by accumulation and
translocation to the nucleus under hypoxic conditions.
While apical regions of all tumors showed higher cytoplas-
mic intensity and nuclear staining of HIF-1a, no differ-
ences between treatment groups were observed (Figure 2C
and Additional file 2, Figure S1).
PKA antagonist treatment of ApcMin/+ mice decreases the
levels b-catenin signaling to the nucleus and of COX-2
and c-Myc expression in ApcMin/+ mice tumors
We next examined the effect of treatment on the activity of
the PGE2- b-catenin pathway in tumor cells. As evident
from image analysis of immunohistochemically stained sec-
tions, levels of b-catenin were significantly decreased in
tumors from the animals treated with the PKA antagonist
Rp-8-Br-cAMPS compared to tumors from the control-
treated group (138 versus 117 median inverse grayscale
intensity units; P < 0.001, Figure 3A, B) Furthermore, the
median number of b-catenin positive nuclei were reduced
from 20% in tumors in the control group to 10% in tumors
in the Rp-8-Br-cAMPS treated group (P = 0.024, Figure 3A,
B and Additional file 3, Figure S2). In addition, expression
of the b-catenin/TCF/LEF transcription complex-regulated
genes c-Myc and COX-2 were reduced in tumor cells upon
treatment with the PKA antagonist Rp-8-Br-cAMPS as evi-
dent from the median number of nuclei positive for c-Myc
(reduced from 60% in control to 20%; P < 0.001, Figure 3A,
B and Additional file 3, Figure S2) and from the cytoplas-
mic expression levels of the COX-2 enzyme (reduced from
136 in control to 106 median inverse grayscale intensity
units in the treated group; P < 0.001, Figure 3A, B and
Additional file 3, Figure S2).
For further quantification of the observed effects on tumor
tissue and validation of the observed effects without dilu-
tion into normal mucosa, we next looked at the regulation
of b-catenin phosphorylation and c-Myc regulation in a
human colonic cancer cell line, HCT 116 (Figure 4A and
4B). While treatment of HCT 116 colon carcinoma cells
with PGE2 for 30 min (phosphorylated b-catenin) or 1 h
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Figure 1 PKA antagonist reduces tumor load in ApcMin/+ mice.
A. Images of developing adenomas representative of each
treatment acquired by transillumination microscopy are shown.
White bars = 500 μm. B. Number (B; left panel) and size (B; mid
panel) of spontaneously occurring tumors and distribution of tumor
size in the treatment groups (B; right panel), tumor numbers/size
class). Box plots with median (horizontal line); 25-75% (box) and 2.5-
97.5% (bar) percentiles are shown for each treatment group (n = 7-
10 as indicated). All tumors from the same animals were pooled
when comparing tumor size distribution between the groups (n =
41-585) as indicated. Mann-Whitney Rank Sum test was used to
compare the groups (SigmaPlot 11.0 (CA, USA). C. Number (C; left
panel) and size (right panel) of spontaneously occurring tumors in
the small intestine relative to the distance from the ventricle.
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(c-Myc) increased phosphorylation of both Ser552 and
Ser675 as well as c-Myc levels, treatment with indometha-
cin or Rp-8-Br-cAMPS reduced levels compared to
untreated sample. The latter indicates some basal prosta-
glandin production and PKA activation, although COX-2
levels are not sufficiently high to allow detection by Wes-
tern blot in HCT 116 cells [25] (and our observations).
Furthermore, the effect of exogenously added PGE2 on b-
catenin Ser552 and Ser 675 phosphorylation could be
blocked by Rp-8-Br-cAMPS but not to the same extent by
indomethacin which cannot inhibit the down-stream effect
of adding PGE2 to the cultures. In contrast, PGE2-
mediated upregulation of c-Myc levels could be blocked in
the presence of indomethacin, which may indicate that the
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Figure 2 Immunohistochemical characterization of lymphocytic infiltration and hypoxia status by HIF-1a in the ApcMin/+ mice tumors.
A. Images acquired by microscopy of intestines from animals treated with PBS showing representative sections of tumor (GZMB, FOXP3) or
normal small intestinal mucosa (CD3, CD8, CD56). Images with H-E stained overview, normal mucosa and tumor are also shown (top, left and
middle three panels). B. Identifiable tumors were photographed and number of positive cells per area (n) in Rp-8-Br-cAMPS and PBS treated
animals were counted using a grid. Tumors and normal tissue from all animals in each group were examined (see Additional file 2, Figure S1 for
more representative images). Date are presented in Box plots with median (horizontal line); 25-75% (box) and 2.5-97.5% (bar) percentiles for each
treatment group. C. The intensity of the HIF-1a staining was calculated as the mean inverse grayscale intensity of tumor area (n). A
representative image from Rp-8-Br-cAMPS treated animal is shown (C; left panel) along with density staining data (C; right panel; Box plots
presented as in B, n = 18-30 tumors examined). Mann-Whitney Rank Sum test was used to compare the groups in B and C; P < 0.05 was
considered significant.
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regulation at this later time point relies more on endogen-
ously produced PGE2.
Cytoplasmic b-catenin may be targeted to proteosomal
degradation through the destruction complex consisting
of GSK3b, Axin, CK1 and APC (Figure 4C). However,
in the presence of active Wnt signaling, b-catenin accu-
mulates in the cytosol and translocates to the nucleus to
act in a mitogenic fashion by transactivation of TCF/
LEF leading to expression of target genes in a cell prolif-
eration and survival program [5]. As is well established,
the Wnt-Frz pathway inhibits the destruction complex
at the level of GSK3b, leading to less proteosomal
degradation and more nuclear translocation and activa-
tion of b-catenin [2]. Similarly, the up-regulation of
COX-2 in colorectal cancer leads to production of PGE2
which binds to the EP3 receptor leading to PI3K and
PKB activation, phosphorylation and dissociation of
GSK3b and thereby inhibition of the destruction com-
plex [26] (Figure 4C). In zebrafish stem cells, PGE2 act-
ing through an EP2/4-cAMP-PKA pathway was recently
shown to induce direct phosphorylation of b-catenin,
thereby stimulating its translocation to the nucleus and
mitogenic effect [18]. Here, we tested whether this sec-
ond pathway was providing a mitogenic drive in
intestinal cancer. Using ApcMin/+ mice with a disturbed
b-catenin degradation, we specifically inhibited the
PGE2-cAMP pathway at the level of PKA by treating
mice with Rp-8-Br-cAMPS for 6 weeks (see, Figure 4C
for point of action). We show that this not only reduces
tumor load but also specifically inhibits b-catenin
nuclear translocation and the activation of b-catenin tar-
get genes such as c-Myc and COX-2 which may indicate
that the direct regulatory effect of PKA on b-catenin
nuclear translocation is also operative in intestinal can-
cer cells. Furthermore, the fact that COX inhibitors may
block the effect of PGE2 both in the b-catenin degrada-
tion and b-catenin nuclear translocation pathways while
Rp-8-Br-cAMPS only affects the latter may explain why
inhibitory effect of the PKA antagonist on tumor pro-
motion is comparably weaker than that of indomethacin.
Finally, our observation that COX inhibitor abolishes
tumor numbers whereas PKA antagonist reduces tumor
load but not tumor numbers may indicate that the anti-
tumorigenic and anti-proliferative effects are distinct
and relate to different points of action in PGE2 signal
pathways. It is interesting to speculate that stem cells in
crypt foci that give origin to adenomas may be more
sensitive to regulation via the Wnt-Frz and PGE2-EP3
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Figure 3 PKA antagonist treatment of ApcMin/+ mice decreased COX-2, b-catenin and c-Myc expression in small intestinal tumor tissue.
A. The intensity of the b-catenin and COX-2 staining was calculated as the mean inverse grayscale intensity of tumor area (Image J 1.43u
software package). Percent b-catenin and c-Myc positive nuclei were also assessed. Data are presented as Box plots with median (horizontal line);
25-75% (box) and 2.5-97.5% (bar) percentiles shown for each treatment group. Median values compared with Mann-Whitney Rank Sum test
when Shapiro-Wilk Normality test failed; otherwise mean values compared by Student’s t-test. N = no. of tumors examined (tumors from every
animal in each treatment group were investigated). B. Micrographs of representative tumors from the PBS and Rp-8-Br-cAMPS (Rp-8-Br) treated
groups stained with b-catenin, c-Myc and COX-2 antibodies.
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pathways than via the EP2/4-cAMP-PGE2 pathway
whereas this balance may shift during tumor
development.
Additional material
Additional file 1: Supplementary information. Materials and Methods.
Reference List [27-29].
Additional file 2: Figure S1. Immunohistochemical staining with
indicated antibodies of tumor and normal mucosa from small intestines
from ApcMin/+ mice treated with PBS or Rp-8-Br-cAMPS.
Additional file 3: Figure S2. Immunohistochemical staining with
indicated antibodies of tumor and normal mucosa from small intestines
from ApcMin/+ mice treated with PBS or Rp-8-Br-cAMPS.
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SUPPLEMENTARY INFORMATION 
to 
Brudvik et al. Protein kinase A antagonist inhibits -catenin nuclear translocation, c-Myc 
and COX-2 expression and tumor promotion in ApcMin/+ mice 
 
Materials and Methods 
Six-week old, female ApcMin/+ mice (PCR-genotyped) obtained by breeding C57BL/6J wild-
type (Apc+/+) females with C57BL/6J ApcMin/+ males (Jackson Laboratory, Bar Harbor, ME) 
were randomized into three groups of 10 animals and treated with Rp-8-Br-cAMPS (Rp-8-Br; 
75 mg/kg, prepared by Lauras AS (Oslo, Norway) [27], previously dose and toxicity tested 
[28], injected i.p. every second day), indomethacin (Indo; 5 mg/kg in ethanol; Sigma-Aldrich, 
MO, USA, delivered by gavage every second day [29]) or PBS (vehicle control , injected i.p. 
every second day) for 6 weeks (standard chow and maintenance, Norwegian Institute of 
Public Health), sacrificed and intestines subsequently examined. Two animals in the Rp-8-Br-
cAMPS group were euthanized during the first 3 weeks due to rectal prolapse; two animals, 
one each from the Rp-8-Br-cAMPS and control groups, were excluded as outliers due to 
tumor numbers > mean + 3SD.  
 
Small and large intestines were cut longitudinally, spread on filter paper, fixed (10% formalin, 
48h), stained with 0.2% methylene blue in 10% formalin and examined by transillumination 
in an inverse light microscope (320x; blinded data acquisition), as described in detail 
elsewhere [30]. The study was approved by the National Animal Research Authority (id: 
FOTS1597) before conducting the experiments. We fully complied with the guidelines issued 
and exercised due consideration. The health of the animals was checked daily. 
 
Immunohistochemistry was performed on sections from the distal third part of the small 
intestine and tumors were analyzed from all animals in each group. Formalin fixed intestines 
were rolled (Fig. 1), embedded in paraffin, subjected to serial sectioning at 3.5 μm and stained 
routinely with hematoxylin and eosin (H-E) or subjected to immunohistochemistry (Lab 
Vision Autostainer 480, AH-Diagnostics, Denmark) using antibodies to CD3 (Abcam, UK; 
0.5 μg/ml), Granzyme B (Abcam, UK; 2.5 μg/ml), CD8 (Santa Cruz, CA, USA; 0.025 
μg/ml), CD56 (Abcam, UK; 5 μg/ml), FOXP3 (Aviva Systems Biology, CA, USA; 1.67 
μg/ml), HIF-1 (Novus Biologicals, CO, USA; 1.67 μg/ml), -catenin (Thermo Fischer 
Scientific, CA, USA; 0.8 μg/ml), c-Myc (Santa Cruz, CA, USA; 4 μg/ml) and COX-2 
(Thermo Fischer Scientific, CA, USA; 0.25 μg/ml) followed by blocking with endogenous 
peroxidase and staining with horseradish peroxidase, then examination in a DM 3000 
microscope with DFC 420 camera (Leica, Germany).  
 
Images captured with a 10x objective were analyzed using Image J 1.43u software package 
(National Institutes of Health, USA). On average 10 sections from each animal were created 
and a total of 1014 images were captured and analyzed (CD3; 138, CD8; 76, CD56; 96, 
GZMB; 155, FOXP3; 100, b-Catenin; 139, COX-2; 161, cMyc; 69 and HIF-1a; 80). The 
intensity of the HIF-1, -catenin and COX-2 staining were calculated as the mean inverse 
grayscale intensity of tumor area: The area of the lesions was marked with the Freehand 
Selection tool and then analyzed by the measure tool to calculate the mean grayscale intensity 
in the area. The mean grayscale was then inverted on the grayscale intensity scale (1-255). To 
exclude the possibility of bias because of background staining, the normal mucosa was 
evaluated using the same method with no differences observed between the treatment groups. 
Furthermore, the size of the tumor area used for grayscale calculations was registered, but 
there was no correlation between tumor number or tumor size and the staining intensity 
(Spearman Correlations R < 0.16, P > 0.05). Moreover, a direct coupling between 
observations grayscale intensity (i.e. -catenin levels) and tumor size was precluded by the 
experimental setup where immunohistochemistry was done on sections (which may not 
represent the true size of the tumor) whereas the tumor size observations came from 
examinations in an inverse light microscope directly on whole mice intestines. SigmaPlot 11.0 
(CA, USA) was used to compare groups and create graphs. A P-value < 0.05 was regarded 
significant. Median values were compared with Mann-Whitney Rank Sum test when Shapiro-
Wilk Normality test failed; otherwise mean values were compared by Student’s t-test. 
Animals with tumor numbers outside three standard deviations from the mean of the group 
were excluded when comparing the groups.  
 
Western blotting was performed on cell lysates from HCT 116 colorectal carcinoma cell line 
(ATCC, VA, USA) after stimulation (PGE2) in the absence or presence of inhibitors 
(indomethacin or Rp-8-Br-cAMPS) for different periods of time (30 min., 1 hour and 2 
hours). The following antibodies were used -catenin, phospho--catenin (Ser552), phospho-
-catenin (Ser675), (Cell Signaling Technology, MA, USA), c-Myc and Actin (Santa Cruz, 
CA, USA). Cell lysates and were analyzed on a 10% SDS/PAGE and blotted onto PVDF 
membranes. The filters were blocked in 5% non-fat dry milk in TBST or 5% BSA (according to 
manufacturers protocol) for 30 min at RT, incubated overnight at 4°C with primary antibodies, 
washed five times 5 min in TBST and incubated with a horseradish-peroxidase-conjugated 
secondary antibody. Blots were developed by using Supersignal West Pico substrate (Pierce, 
Rockford, IL, USA) and exposure of film and Image J software was next used for quantification 
of the immunoreactive signals. 
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